Cover Page
Cover Page - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 23, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 001-39378 | ||
Entity Registrant Name | ORIGIN MATERIALS, INC. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 87-1388928 | ||
Entity Address, Address Line One | 930 Riverside Parkway | ||
Entity Address, Address Line Two | Suite 10 | ||
Entity Address, City or Town | West Sacramento, | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 95605 | ||
City Area Code | 916 | ||
Local Phone Number | 231-9329 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 526.3 | ||
Entity Common Stock, Shares Outstanding | 145,917,486 | ||
Documents Incorporated by Reference | Specified portions of the registrant’s definitive proxy statement to be issued in conjunction with the registrant’s 2024 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2023 (“Proxy Statement”), are incorporated by reference into Part III of this Annual Report on Form 10-K (this “Annual Report”). Except as expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be a part of this Annual Report. | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0001802457 | ||
Common Stock | |||
Document Information [Line Items] | |||
Title of 12(b) Security | Common Stock, $0.0001 par value per share | ||
Trading Symbol | ORGN | ||
Security Exchange Name | NASDAQ | ||
Warrant | |||
Document Information [Line Items] | |||
Title of 12(b) Security | Warrants | ||
Trading Symbol | ORGNW | ||
Security Exchange Name | NASDAQ |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Audit Information [Abstract] | |
Auditor Firm ID | 34 |
Auditor Name | DELOITTE & TOUCHE LLP |
Auditor Location | Sacramento, California |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets | ||
Cash and cash equivalents | $ 75,502 | $ 107,858 |
Restricted cash | 0 | 490 |
Marketable securities | 82,761 | 215,464 |
Accounts receivable and unbilled receivable, net | 16,128 | 0 |
Other receivables | 3,449 | 4,346 |
Inventory | 912 | 0 |
Prepaid expenses and other current assets | 8,360 | 3,341 |
Total current assets | 187,112 | 331,499 |
Property, plant, and equipment, net | 243,118 | 154,183 |
Operating lease right-of-use asset | 4,468 | 2,779 |
Intangible assets, net | 121 | 160 |
Deferred tax assets | 1,261 | 0 |
Other long-term assets | 25,754 | 5,079 |
Total assets | 461,834 | 493,700 |
Current liabilities | ||
Accounts payable | 1,858 | 10,384 |
Accrued expenses | 7,689 | 8,414 |
Operating lease liabilities, current | 367 | 619 |
Notes payable, short-term | 1,730 | 0 |
Other liabilities, current | 918 | 51 |
Derivative liability | 300 | 344 |
Total current liabilities | 12,862 | 19,812 |
Earnout liability | 1,783 | 42,533 |
Canadian Government Research and Development Program liability | 7,348 | 7,185 |
Common stock warrants liability | 1,341 | 30,872 |
Notes payable, long-term | 3,459 | 5,847 |
Operating lease liabilities | 4,207 | 2,249 |
Other liabilities, long-term | 8,327 | 8,297 |
Total liabilities | 39,327 | 116,795 |
Commitments and contingencies (See Note 18) | ||
STOCKHOLDERS’ EQUITY | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 145,706,531 and 143,034,225, issued and outstanding as of December 31, 2023 and 2022, respectively (including 4,500,000 Sponsor Vesting Shares) | 15 | 14 |
Additional paid-in capital | 382,854 | 371,072 |
Retained earnings | 45,570 | 21,772 |
Accumulated other comprehensive loss | (5,932) | (15,953) |
Total stockholders’ equity | 422,507 | 376,905 |
Total liabilities and stockholders’ equity | $ 461,834 | $ 493,700 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued (in shares) | 145,706,531 | 143,034,225 |
Common stock, shares outstanding (in shares) | 145,706,531 | 143,034,225 |
Sponsor vesting shares issued (in shares) | 4,500,000 | 4,500,000 |
Sponsor vesting shares outstanding (in shares) | 4,500,000 | 4,500,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Income - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues [Abstract] | ||
Total revenues | $ 28,805 | $ 0 |
Cost of revenues (exclusive of depreciation and amortization shown separately below) | 23,591 | 0 |
Operating expenses | ||
Research and development | 21,351 | 14,141 |
General and administrative | 35,382 | 24,095 |
Depreciation and amortization | 3,363 | 711 |
Total operating expenses | 60,096 | 38,947 |
Loss from operations | (54,882) | (38,947) |
Other income (expenses) | ||
Interest income | 6,303 | 8,825 |
Interest expenses | (131) | 0 |
Gain (loss) in fair value of derivatives | 69 | (443) |
Change in fair value of common stock warrants liability | 29,531 | 21,988 |
Gain in fair value of earnout liability | 40,983 | 85,437 |
Other income, net | 838 | 1,709 |
Total other income, net | 77,593 | 117,516 |
Income before income tax benefits | 22,711 | 78,569 |
Income tax expenses | 1,087 | 0 |
Net income | 23,798 | 78,569 |
Other comprehensive income (loss) | ||
Unrealized gain (loss) on marketable securities, net of tax | 6,355 | (8,014) |
Foreign currency translation adjustment, net of tax | 3,666 | (6,688) |
Total other comprehensive income (loss) | 10,021 | (14,702) |
Total comprehensive income | $ 33,819 | $ 63,867 |
Net income per share, basic (in dollars per share) | $ 0.17 | $ 0.57 |
Net income per share, diluted (in dollars per share) | $ 0.17 | $ 0.55 |
Weighted-average common shares outstanding, basic (in shares) | 139,718,385 | 137,563,877 |
Weighted-average common shares outstanding, diluted (in shares) | 142,658,423 | 142,146,767 |
Products | ||
Revenues [Abstract] | ||
Total revenues | $ 23,896 | $ 0 |
Services | ||
Revenues [Abstract] | ||
Total revenues | $ 4,909 | $ 0 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Retained Earnings (Accumulated Deficit) | Accumulated Other Comprehensive loss |
Balance beginning (in shares) at Dec. 31, 2021 | 141,301,569 | ||||
Balance beginning at Dec. 31, 2021 | $ 303,510 | $ 16 | $ 361,542 | $ (56,797) | $ (1,251) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Common stock issued upon exercise of stock options (in shares) | 1,412,226 | ||||
Common stock issued upon exercise of stock options | 401 | 401 | |||
Vested common stock awards (in shares) | 320,430 | ||||
Vested common stock awards | (2) | $ (2) | |||
Stock-based compensation | 9,129 | 9,129 | |||
Net income | 78,569 | 78,569 | |||
Other comprehensive income (loss) | (14,702) | (14,702) | |||
Ending balance at Dec. 31, 2022 | 376,905 | $ 14 | 371,072 | 21,772 | (15,953) |
Ending balance (in shares) at Dec. 31, 2022 | 143,034,225 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Common stock issued upon exercise of stock options (in shares) | 959,143 | ||||
Common stock issued upon exercise of stock options | 146 | 146 | |||
Vested common stock awards (in shares) | 1,713,163 | ||||
Vested common stock awards | 1 | $ 1 | |||
Stock-based compensation | 11,636 | 11,636 | |||
Net income | 23,798 | 23,798 | |||
Other comprehensive income (loss) | 10,021 | 10,021 | |||
Ending balance at Dec. 31, 2023 | $ 422,507 | $ 15 | $ 382,854 | $ 45,570 | $ (5,932) |
Ending balance (in shares) at Dec. 31, 2023 | 145,706,531 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash flows from operating activities | ||
Net income | $ 23,798 | $ 78,569 |
Adjustments to reconcile net income to net cash used in operating activities: | ||
Depreciation and amortization | 3,363 | 711 |
Amortization on right-of-use asset | 615 | 582 |
Stock-based compensation | 9,400 | 7,235 |
Realized gain on marketable securities | (1,018) | 0 |
Amortization of premium and discount of marketable securities, net | 3,750 | 0 |
Change in fair value of derivative | (69) | 443 |
Change in fair value of common stock warrants liability | (29,531) | (21,988) |
Change in fair value of earnout liability | (40,983) | (85,437) |
Deferred tax benefits | (1,246) | 0 |
Changes in operating assets and liabilities: | ||
Accounts and other receivables | (15,230) | (1,734) |
Inventory | (912) | 0 |
Prepaid expenses and other current assets | (4,994) | 432 |
Other long-term assets | (12,761) | (5,017) |
Accounts payable | 909 | 26 |
Accrued expenses | 4,985 | 485 |
Operating lease liability | (534) | (572) |
Other liabilities, current | 65 | (329) |
Other liabilities, long-term | 38 | 502 |
Net cash used in operating activities | (60,355) | (26,092) |
Cash flows from investing activities | ||
License prepayment within other long-term assets | (7,913) | 0 |
Purchases of property, plant, and equipment | (102,188) | (83,691) |
Purchases of marketable securities | (3,626,305) | (3,823,407) |
Sales of marketable securities | 3,605,216 | 3,815,859 |
Maturities of marketable securities | 157,422 | 180,331 |
Capitalized interest on plant construction | 0 | (245) |
Net cash provided by investing activities | 26,232 | 88,847 |
Cash flows from financing activities | ||
Proceeds from Canadian Government Research and Development Program | 0 | 849 |
Proceeds from exercise of stock options | 146 | 399 |
Net cash provided by financing activities | 146 | 1,248 |
Effects of foreign exchange rate changes on the balance of cash and cash equivalents, and restricted cash held in foreign currencies | 1,131 | (2,782) |
Net (decrease) increase in cash and cash equivalents, and restricted cash | (32,846) | 61,221 |
Cash and cash equivalents, and restricted cash, beginning of the period | 108,348 | 47,127 |
Cash and cash equivalents, and restricted cash, end of the period | 75,502 | 108,348 |
Supplemental disclosure of cash flow information | ||
Operating lease ROU assets obtained in exchange for lease obligations | 2,308 | 1,687 |
Stock-based compensation capitalized into property, plant, and equipment | 2,236 | 1,894 |
Purchases of fixed assets included in accounts payable and accrued expenses | 1,939 | 17,085 |
Accrued interest capitalized into property, plant, and equipment | 367 | 0 |
Cash paid during the period: | ||
Income taxes payment | $ 129 | $ 0 |
Organization and Business
Organization and Business | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Business | Organization and Business Unless the context otherwise requires, references in these notes to “Origin”, “the Company”, “we”, “us” and “our” and any related terms are intended to mean Origin Materials, Inc. and its consolidated subsidiaries. In June 2021, Artius Acquisition Inc. (“Artius”), a special purpose acquisition company, completed a business combination and merger with Micromidas, Inc., a Delaware corporation (now known as Origin Materials Operating Inc., (“Legacy Origin”)), Pursuant to the terms of the Merger Agreement (a business combination between Artius and Legacy Origin, the “Merger Agreement”) under which Legacy Origin became a wholly-owned subsidiary of Artius (the “Merger”) and Artius changed its name to Origin Materials, Inc. (collectively with its subsidiaries, the “Company”). The Company's mission to help enable the world’s transition to sustainable materials. Our innovative technologies include all-PET caps and closures that bring recycling circularity and enhanced performance to a greater than $65 billion market, specialty materials, and our patented biomass conversion platform that transforms carbon into sustainable materials for a wide range of end products addressing a ~$1 trillion market including food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments and more. The Company’s biomass conversion technology can transform sustainable feedstocks, such as sustainably harvested wood, agricultural waste, wood waste and corrugated cardboard, into materials and products that are currently made from fossil feedstocks, such as petroleum and natural gas. The Company achieved the mechanical completion of its first manufacturing plant in Ontario, Canada (“Origin 1”), the world’s first commercial chloromethylfurfural (“CMF”) plant, and the plant is currently fully operational. The Company is also currently in the planning phase for the construction of a significantly larger manufacturing plant (“Origin 2”). |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of revenues, costs and expenses during the reporting periods. Estimates made by the Company include, but are not limited to, valuation of the earnout liability, carrying amount and useful lives of property and equipment and intangible assets, impairment assessments, probabilities of achievement of performance conditions on performance stock awards. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Principles of Consolidation The consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents, marketable securities and accounts receivable. The Company maintains its cash, cash equivalents, and marketable securities accounts with financial institutions where, at times, deposits exceed federal insurance limits. Management believes that the Company is not currently exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. While the Company has not experienced losses of these deposits to date, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected. For accounts receivable, as of December 31, 2023, our top two customers from product sales, in the aggregate, accounted for approximately 67% of total accounts receivable outstanding balances and accounted for approximately 77% of total revenue for the year ended December 31, 2023. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts. Restricted cash consists of cash held in a control account as collateral for the Company’s escrow services and standby letter of credit. These restricted cash balances have been excluded from cash and cash equivalents balance in the consolidated balance sheets based on the contractual terms. The Company entered into an escrow agreement on September 27, 2019 for $1.3 million, whereby the funds would be used for construction and transportation services in connection with Origin 1. At December 31, 2023 and 2022, the escrow account had a balance of zero and $0.3 million, respectively. On June 27, 2023, the Company began startup of the Origin 1 facility. Therefore, those funds are no longer restricted and have been released. The Company had a standby letter of credit, whereby the funds were used for the completion of work, services, and improvements in connection with Origin 1. The standby letter of credit matured and automatically renewed in October of each year. At December 31, 2023 and 2022, the standby letter of credit was zero and $0.2 million, respectively. On June 27, 2023, the Company began startup of the Origin 1 facility. Therefore, those funds are no longer restricted and have been released. Cash, cash equivalents, and restricted cash consisted of the following (in thousands): December 31, 2023 December 31, 2022 Cash and cash equivalents $ 75,502 $ 107,858 Restricted cash — 490 Total cash, cash equivalents, and restricted cash $ 75,502 $ 108,348 Marketable Securities The Company’s investment policy requires the Company to purchase investments that are consistent with the classification of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component in the consolidated statements of operations and comprehensive income until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses. Expected credit losses on securities are recognized in other income, net in the consolidated statements of operations and comprehensive income, and any remaining unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss in the consolidated statements of stockholders’ equity. For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Amortization of discounts and premiums, net, and interest on securities classified as available for sale are included as a component of interest income within other income (expenses). The nature of these financial instruments include instruments for which quoted prices are available but traded less frequently, instruments whose fair value has been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data, and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 2 financial instruments include agency mortgage-backed securities, corporate fixed income securities infrequently traded, and other securities, which primarily consist of sovereign debt, U.S. government agency securities, loans, and state and municipal securities. Derivative Financial Instruments The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the consolidated balance sheets. Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized in the change in fair value of derivatives within other income (expenses). While the contract or notional amount is often used to express the volume of foreign currency derivative contracts, the amounts potentially subject to credit risk are generally limited to the amounts, if any, by which the counterparties’ obligations under the agreements exceed the obligations of the Company to the counterparties. Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3). Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market. The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. The fair values of cash equivalents and the Common Stock Warrants which are publicly traded are level 1 inputs. The fair value of the Common Stock Warrants which are not publicly traded, marketable securities, and foreign currency derivative contracts are level 2 inputs as the Company uses quoted market prices or alternative pricing sources and models utilizing observable market inputs. The earnout liability was estimated using Level 3 inputs. Accounts Receivable and unbilled services, net We record accounts receivable at the stated amount of the transactions with our customers, and we do not charge interest. The allowance for credit losses, known as the Current Expected Credit Losses (“CECL”) model, is our best estimate of the amount of probable credit losses associated with our accounts receivable. We determine the allowance based on current conditions, and reasonable and supportable forecasts. Past-due balances are reviewed individually for collectability. We charge off account balances against the allowance after we have exhausted all means of collection and we consider the potential for recovery to be remote. Our accounts receivable generally have net 30 to net 90-day payment terms, and we usually receive consideration in accordance with the payment terms of the contract. As of December 31, 2023 and 2022, we do not have any allowance for credit losses. Unbilled receivables arise when the timing of cash collected from customers differs from the timing of revenue recognition for the obligations performed. December 31, 2023 December 31, 2022 Accounts receivable, gross $ 15,204 $ — Allowance for credit loss — — Unbilled receivable 924 — Accounts receivable, net $ 16,128 $ — Other Receivables Other receivables consist of amounts due from foreign governmental entities related to the Canadian harmonized sales tax (“HST”) and goods and services tax (“GST”) for goods and services transacted in Canada, and amounts due from cash collateral held by others for foreign currency derivative contracts. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using a weighted-average cost approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value. Property, Plant, and Equipment Additions to property, plant, and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated economic useful lives of the respective assets. The estimated useful lives of assets are as follows: Computer equipment and software 3 years Lab equipment 5 years Furniture, fixtures, and machinery 5 years Land improvements and infrastructure 20 years Manufacturing equipment and pilot plant 25 years Buildings 40 years Land is non-amortizing. Computer equipment and software includes an immaterial amount of internal use software. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to expenses. Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is charged to income or loss from operations. Costs incurred to acquire, construct or install property, plant, and equipment during the construction stage of a capital project and costs capitalized in conjunction with major improvements that have not yet been placed in service are recorded as construction in progress, and accordingly are not currently being depreciated. The Company capitalizes stock-based compensation expenses and interest cost incurred on funds used to construct property, plant and equipment. Intangible Assets Intangible assets are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the respective assets, ranging from 7 to 15 years. The cost of servicing the Company’s patents is expensed as incurred. Upon retirement or sale, the cost of intangible assets is disposed of and the related accumulated amortization is removed from the accounts. Impairment of Long-Lived Assets The Company reviews its long-lived assets, including property, equipment, software and intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If indicators of impairment exist, management identifies the asset group which includes the potentially impaired long-lived asset, at the lowest level at which there are separate, identifiable cash flows. If the total of the expected undiscounted future net cash flows for the asset group is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. For the year ended December 31, 2023 and 2022, no impairment was identified. Common Stock Warrants Liability The Company assumed 24,149,960 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Common Stock Warrants” or “Warrants”) upon the Merger, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A common stock at an exercise price of at $11.50 per share. As of December 31, 2023, 24,149,960 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the Public Warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants. There were no Private Placement Warrants that became Public Warrants as of Dec 31, 2023. The Company evaluated the Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”) , and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the Common Stock Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves 50% or more of our Class A stockholders. Because not all of the voting stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Common Stock Warrants do not meet the conditions to be classified in equity. Since the Common Stock Warrants meet the definition of a derivative under ASC 815, the Company recorded these Warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the gain in fair value of common stock warrant liabilities within the consolidated statements of operations and comprehensive income at each reporting date. The Public Warrants were publicly traded and thus had an observable market price to estimate fair value, and the Private Placement Warrants were effectively valued similar to the Public Warrants, as described in Note 5. Earnout Liability The Company has recorded an earnout liability related to future contingent equity shares related to the Merger (Note 12). The Company recorded these instruments as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date. Leases We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a finance lease. The Company has leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC 842, Leases . The Company recognizes a right-of-use (“ROU”) asset and lease liability for leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain to be exercised. Revenue Recognition The Company began to recognize revenue in 2023. Our revenues are from product sales and service agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct—that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) . The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or service to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and service agreements, we perform the following steps: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations; and 5. Recognizing revenue when, or as, the performance obligations are satisfied. We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer. Our service agreements are customized, specified, and often include various stages at which transaction prices are agreed to. These service agreements often include multiple performance obligations within each stage. We identify each performance obligation at contract inception and allocate the consideration to each distinct performance obligation based on the stand-alone selling price of each performance obligation. Our services are tailored to each individual customer and the stand-alone selling prices are not directly observable. As our service agreements include customers that are not in similar geographic markets and for different services, therefore the Company uses the expected cost plus margin approach to estimate the stand-alone selling price for each of our performance obligations. We recognize revenue from the service agreements over the period during which the services are performed and recognize the associated costs as they are incurred. In general, we recognize revenue when, or as, our performance obligations under the terms of a contract with our customer are satisfied. For product sales, this happens when we transfer control of our products and risk of loss to the customer or when title passes upon shipment. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring our products. Taxes collected from customers and remitted to governmental authorities are excluded from revenues. The Company recognizes its revenue from direct product sales which is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. For service agreements, the timing of satisfying performance obligations may differ from the timing of the invoicing of customers and the receipt of customer payments. The Company records a receivable prior to payment if there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records contract liability (deferred income) until the performance obligations are satisfied. Revenue is recorded in an amount that reflects that consideration we expect to be entitled to in exchange for those goods or services. We have elected to treat shipping and handling activities as fulfillment costs. Cost of revenues Cost of revenues for product sales consists primarily of cost associated with the purchase of finished goods. Cost of revenues for service agreements is based on the actual cost incurred, which mainly consists of the direct cost from vendors and overhead costs such as payroll and benefit related to our employees who provide the services to customers. Research and Development Cost Costs related to research and development are expensed as incurred. Stock-Based Compensation The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. In addition, the Company capitalizes stock-based compensation related to employees whose costs are necessary to bring the asset to its intended use. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including: • Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term. • Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor. • Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future. • Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate. • Risk-free interest rate – The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with the same or substantially equivalent remaining term. Workforce Reduction Costs In November 2023, we announced a plan for a workforce reduction of approximately 30% of our total workforce to realign and optimize our workforce requirements in alignment with our refined corporate strategy. The Company aims to focus on cash conservation and affected an organizational realignment to reflect the deferral of research programs with longer-term economic impacts and the acceleration of higher margin revenue opportunities. Workforce reduction costs primarily consisted of severance and benefits costs associated with the workforce reduction in November 2023 (see Note 15). As of December 31, 2023, we do not expect to record any significant future charges related to the workforce reduction plan. Income Taxes Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters as a component of income tax expense. Functional Currency Translation The functional currency of the Company’s wholly-owned Canadian subsidiaries is the Canadian dollar, whereby their assets and liabilities are translated at period-end exchange rates except for non-monetary capital transactions and balances, which are translated at historical rates. All income and expense amounts of the Company are translated at average exchange rates for the respective period. Translation gains and losses are not included in determining net income but are accumulated in a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the determination of net income in the period in which they occur. These amounts are included in other income, net, of the consolidated statements of operations and comprehensive income. Comprehensive Income (Loss) The Company’s comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Foreign currency translation gains or losses and unrealized gains or losses on available-for-sale marketable debt securities are included in the Company’s other comprehensive income (loss). Basic and Diluted Net Income Per Share Basic net income per common share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net income per share is computed by dividing the net income attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net income per share calculation, common stock options, RSU awards, performance stock awards, warrants, earnout shares, and Sponsor Vesting Shares (as defined in Note 12) are considered to be potentially dilutive securities. For the periods presented that the Company has reported a net loss, diluted net loss per common share is the same as basic net loss per common share for those periods. Reclassifications Certain amounts on the consolidated balance sheets as of December 31, 2022 have been condensed to conform with the current presentation for the year ended December 31, 2023. Segment Reporting The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company has determined that its Co-Chief Executive Officers are the CODM. As of and for the year ending December 31, 2023, the Company’s CODM has made such decisions and assessed performance at the Company level. |
Recent Accounting Pronouncement
Recent Accounting Pronouncements | 12 Months Ended |
Dec. 31, 2023 | |
Recent Accounting Pronouncements [Abstract] | |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (“Topic 815”). This update clarifies the guidance in Topic 815 on fair value hedge accounting of interest rate risk for portfolios and financial assets. Among other things, the amended guidance established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible and renamed that method the “portfolio layer” method. ASU 2022-01 is effective January 1, 2023. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (“Topic 280”) - Improvements to Reportable Segment Disclosures , which updates disclosures about a public entity’s reportable segments, including more detailed information about a reportable segment’s expenses. The amendments in this update require that we disclose (i) on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss (collectively referred to as the “significant expense principle”), (ii) on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition. The other segment items category is the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each reported measure of segment profit or loss, (iii) annual disclosures about a reportable segment’s profit or loss and assets currently required by Topic 280 in interim periods, (iv) clarify that if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources, we may report one or more of those additional measures of segment profit. However, at least one of the reported segment profit or loss measures (or the single reported measure, if only one is disclosed) should be the measure that is most consistent with the measurement principles used in measuring the corresponding amounts in the public entity’s consolidated financial statements, (v) the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (vi) requires that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. This guidance is required to be applied retrospectively to all prior periods presented in the financial statements. This guidance is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements, other than additional disclosures in our notes to the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (“Topic 740”) - Improvements to Income Tax Disclosures, to provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The amendments in this update require that on an annual basis we (i) disclose specific categories in the rate reconciliation, (ii) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate), (iii) disclose additional information about income taxes paid and expensed disaggregated by federal, state, and foreign taxes, and (iv) disclose income (loss) from continuing operations before income tax expense disaggregated between domestic and foreign. The guidance should be applied on a prospective basis however a retrospective application is permitted. The guidance is effective for the Company for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements, other than additional disclosures in our notes to the consolidated financial statements. |
Revenue
Revenue | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Revenue The Company began to recognize revenue during the year ended December 31, 2023. We recognize revenue when, or as, our performance obligations under the terms of a contract with our customer are satisfied. We generally procure, will produce, and sell product to be utilized in the manufacturing of finished products, for which we recognize revenue upon shipment. Our service contracts generally pay us at the commencement of the agreement and then at additional intervals as outlined in each contract. We recognize contract liabilities for such payments and then recognize revenue as we satisfy the related performance obligations. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for such unbilled consideration. We recognize revenue from the service agreements over the period during which the services are performed. The Company did not receive payment before the provision of services during the year ended December 31, 2023 and 2022. Therefore, deferred income is zero as of December 31, 2023 and 2022. |
Fair Value Measurement
Fair Value Measurement | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement | Fair Value Measurement The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows: Fair Value as of December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 75,502 $ — $ — $ 75,502 Marketable securities — 82,761 — 82,761 Total fair value $ 75,502 $ 82,761 $ — $ 158,263 Liabilities: Common stock warrants (Public) $ 913 $ — $ — $ 913 Common stock warrants (Private Placement) — 428 — 428 Earnout liability — — 1,783 1,783 Derivative liability — 300 — 300 Total fair value $ 913 $ 728 $ 1,783 $ 3,424 Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 108,348 $ — $ — $ 108,348 Marketable securities — 215,464 — 215,464 Total fair value $ 108,348 $ 215,464 $ — $ 323,812 Liabilities: Common stock warrants (Public) $ 21,015 $ — $ — $ 21,015 Common stock warrants (Private Placement) — 9,856 — 9,856 Earnout liability — — 42,533 42,533 Derivative liability — 344 — 344 Total fair value $ 21,015 $ 10,200 $ 42,533 $ 73,748 The Company performs routine procedures such as comparing prices obtained from independent sources to ensure that appropriate fair values are recorded. The cash, cash equivalents and public common stock warrants are categorized as Level 1 instruments as the fair value was determined based on the unadjusted quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The marketable securities and derivative liability are categorized as Level 2 instruments as the estimated fair value was determined based on the estimated or actual bids and offers of the marketable securities in an over-the-counter market on the last business day of the year. The common stock warrants are classified within Level 1 or Level 2 because the transfer of Private Placement Warrants to anyone outside of certain permitted transferees of Artius Acquisition Partners LLC (the “Sponsor”) would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is consistent with that of a Public Warrant. Accordingly, the Private Placement Warrants are classified as Level 2 financial instruments. The value of the earnout liability is classified as Level 3 measurements under the fair value hierarchy, as these liabilities have been valued based on significant inputs not observable in the market (see Note 12). A gain of $41.0 million and $85.4 million during the year ended December 31, 2023 and 2022, respectively, was recorded on the consolidated statements of operations and comprehensive income in the gain in fair value of earnout liability. The following table summarized the activities for the earnout liability: December 31, 2023 December 31, 2022 Balance at beginning of period $ 42,533 $ 127,757 Changes in fair value of earnout liability (40,983) (85,437) Other 233 213 Balance at end of period $ 1,783 $ 42,533 As of December 31, 2023 and 2022, the carrying values of accounts receivable, accounts payable, accrued liabilities and deferred income approximate their respective fair values due to their short-term nature. We have determined the fair value of notes payable approximates the carrying value due to the standard terms of the arrangement including but not limited to the amount borrowed, the term, and the interest rate. Marketable Securities The Company’s marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. Amortized cost net of unrealized gain (loss) is equal to fair value. The following table summarized the marketable securities by major security type as follows: As of December 31, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 21,869 $ 26 $ (847) $ 21,048 Asset-backed securities 52,199 26 (2,289) 49,936 U.S. government and agency securities 11,706 — (270) 11,436 Foreign government and agency securities 372 — (31) 341 Total marketable securities $ 86,146 $ 52 $ (3,437) $ 82,761 As of December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 17,568 $ 38 $ — $ 17,606 Corporate bonds 115,134 — (4,923) 110,211 Asset-backed securities 70,825 8 (3,885) 66,948 U.S. government and agency securities 19,308 — (917) 18,391 Foreign government and agency securities 375 — (37) 338 Municipal/provincial bonds and other 2,000 — (30) 1,970 Total marketable securities $ 225,210 $ 46 $ (9,792) $ 215,464 The realized gains and losses are included in other income, net in the consolidated statements of operations and comprehensive income. We sold marketable securities for proceeds of $3,605.2 million and $3,815.9 million during the year ended December 31, 2023 and 2022, respectively. As a result of those sales, we realized a gain of $1.0 million and a loss of $1.0 million during the year ended December 31, 2023 and 2022, respectively. We regularly review our available-for-sale marketable securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The aggregate fair value of the marketable securities in unrealized loss position was $73.2 million and $193.5 million as of December 31, 2023 and 2022, respectively. The unrealized losses were attributable to changes in interest rates that impacted the value of the investments, and not related to increased credit risk. Accordingly, we have not recorded an allowance for credit losses associated with these investments. The contractual maturities of the investments classified as marketable securities are as follows: As of December 31, 2023 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Corporate bonds $ 20,756 $ 292 $ — $ 21,048 Asset-backed securities 238 1,806 47,892 49,936 U.S. government and agency securities 8,929 — 2,507 11,436 Foreign government and agency securities 341 — — 341 Total marketable securities $ 30,264 $ 2,098 $ 50,399 $ 82,761 As of December 31, 2022 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Commercial paper $ 17,606 $ — $ — $ 17,606 Corporate bonds 74,797 35,414 — 110,211 Asset-backed securities 1,907 4,833 60,207 66,947 U.S. government and agency securities 7,719 7,480 3,192 18,391 Foreign government and agency securities — 338 — 338 Municipal/provincial bonds and other 1,971 — — 1,971 Total marketable securities $ 104,000 $ 48,065 $ 63,399 $ 215,464 Derivative Asset and Liabilities The Company entered into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to certain marketable securities denominated in foreign currency. Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized as other income (expenses). During the year ended December 31, 2023 and 2022, the Company recognized a net gain of $0.1 million and a net loss of $0.4 million, respectively, on the fair value adjustment of the foreign currency derivative contracts. The notional amount of foreign currency derivative contracts as of December 31, 2023 and 2022 was $14.7 million and $21.2 million, respectively. |
Property, Plant and Equipment
Property, Plant and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment | Property, Plant and Equipment Property, plant, and equipment consisted of the following: (in thousands) Estimated useful lives December 31, 2023 December 31, 2022 Land $ 11,356 $ 11,358 Land improvements and infrastructure 20 years 62,930 — Manufacturing equipment and pilot plant 25 years 116,754 4,599 Computer equipment and software 3 years 1,629 598 Lab equipment 5 years 3,468 2,526 Furniture, fixtures, and machinery 5 years 1,094 948 Total 197,231 20,029 Less accumulated depreciation and amortization (8,136) (4,693) Construction in process 54,023 138,847 Total property, plant, and equipment, net $ 243,118 $ 154,183 For the year ended December 31, 2023 and 2022, depreciation and amortization expense totaled $3.3 million and $0.7 million, respectively. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Intangible Assets Intangible assets consisted of the following: (in thousands) December 31, 2023 December 31, 2022 Patents $ 413 $ 404 Less accumulated amortization (292) (244) Total intangible assets $ 121 $ 160 The weighted average remaining useful life of the patents was 3.41 years. For the year ended December 31, 2023 and 2022, amortization expense was immaterial and annual amortization expense over the remaining useful life is not expected to be material. |
Consortium Agreement
Consortium Agreement | 12 Months Ended |
Dec. 31, 2023 | |
Transfers and Servicing [Abstract] | |
Consortium Agreement | Consortium Agreement In December 2016, the Company entered into a consortium agreement with two Legacy Origin Series B preferred stock investors to collaborate on development of a process to commercialize bio-based, decarbonizing materials for application on an industrial scale at a competitive price. Under the consortium agreement, the Company received $0.5 million. The agreement expires once performance of the research and development program has been completed. In August 2018, the agreement was amended, whereby a Legacy Origin Series C preferred stock investor (the “Legacy Origin Series C Investor”, and collectively with the two Legacy Origin Series B investors, the “Legacy Origin Investors”) was added to the agreement and committed to invest $1.5 million of research and development in the consortium. As of December 31, 2023, the Legacy Origin Series C Investor had not invested any funds in the consortium. In 2020, an additional counterparty was added to the consortium agreement. During the year ended December 31, 2023 and 2022, the Company did not receive any funds under the consortium agreement. |
Inventory
Inventory | 12 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory | Inventory Inventory balances consist of the following: (in thousands) December 31, 2023 December 31, 2022 Finished goods $ 24 $ — Raw materials 888 — Total $ 912 $ — |
Notes Payable
Notes Payable | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Notes Payable | Notes Payable The Company maintains eight separate offtake supply agreements (the “Offtake Agreements”). Two of the eight Offtake Agreements are with the same customer and pertain to supply of product from Origin 1 and Origin 2, respectively. Legacy Origin received a $5.0 million prepayment from a customer for product from Origin 1 pursuant to one of these Offtake Agreements, which Legacy Origin entered into in November 2016. The prepayment was to be credited against the purchase of products over the term of the Offtake Agreement. The prepayment was secured by a promissory note (the “Promissory Note”) to be repaid in cash in the event that the prepayment could not be credited against the purchase of product, for example, if Origin 1 was never constructed. The Promissory Note was collateralized substantially by Origin 1 and other assets of Origin Materials Canada Pioneer Limited. In May 2019, Legacy Origin and the customer amended the Offtake Agreement and Promissory Note. The amendment added accrued interest of $0.2 million to the principal balance of the prepayment and provided for the prepayment amount to be repaid in three annual installments rather than being applied against the purchase of product from Origin 1. On August 1, 2022, the Company and the customer further amended and restated the Promissory Note with an aggregate principal amount of $5.2 million, which is the sum of the original principal with accrued interest prior to the amendment. As a result of the amendment, the repayment dates were revised and to allow the customer to offset amounts owed for the purchase of product from the Company’s Origin 1 facility against amounts due under the Promissory Note. The repayment in the amount of $2.7 million is due on September 1, 2024, $1.9 million is due on September 1, 2025, and $1.8 million is due on September 1, 2026 (inclusive of accrued but unpaid interest of 3.5% per annum). At December 31, 2023 the total note principal outstanding was $5.2 million of which $3.5 million was included in notes payable, long-term, $1.7 million notes payable, short-term, and $0.8 million unpaid accrued interest recorded in other liabilities, current. At December 31, 2022, the note principal balance was $5.2 million with outstanding accrued interest of $0.6 million was included in notes payable, long-term. In addition, the amendment reflected the customer’s exercise of its option to enter into a new Offtake Agreement to buy a specified annual amount of product from Origin 2 for an initial term of up to 10 years. |
Other Liabilities, Long-term
Other Liabilities, Long-term | 12 Months Ended |
Dec. 31, 2023 | |
Other Liabilities Disclosure [Abstract] | |
Other Liabilities, Long-term | Other Liabilities, Long-term In September 2019, Legacy Origin entered into a $5.0 million prepayment agreement with a counterparty for the purchase of products from Origin 1. The prepayment is to be made in two equal installments: the first $2.5 million was paid in October 2019 and the remaining $2.5 million is due within 30 days of the customer confirming that a sample from Origin 1 meets the customer’s specifications. The Company and customer agreed to work in good faith to execute an Offtake Agreement, the agreed terms of which are set forth in the prepayment agreement, whereby 100% of the prepayment will be applied against future purchases. The prepayment agreement provides the customer a capacity reservation of up to a specified annual volume of product from Origin 1 for a term of ten years, pursuant to the terms of an Offtake Agreement. At December 31, 2023 and 2022, the total amount outstanding on this agreement was $2.5 million. On February 5, 2024, the parties entered into a memorandum of understanding by which they agreed that the counterparty would be released from its obligation to pay the remaining $2.5 million of the prepayment and that Legacy Origin would refund the first $2.5 million within a certain period after reporting in its Quarterly Report on Form 10-Q that its cash on hand has crossed a specified threshold. |
Earnout Liability
Earnout Liability | 12 Months Ended |
Dec. 31, 2023 | |
Earnout Liability Disclosure [Abstract] | |
Earnout Liability | Earnout Liability As additional consideration for the Merger, within ten (a) the volume weighted average price of Common Stock (“VWAP”) equaling on exceeding $15.00 for ten three (b) the VWAP equaling or exceeding $20.00 for ten four (c) the VWAP equaling or exceeding $25.00 for ten five A Sponsor Letter Agreement was delivered in connection with the Merger such that 4.5 million of the shares held by Sponsor (“Sponsor Vesting Shares”) shall be subject to forfeiture based on the same vesting requirements as the Earnout Shares. These shares shall not be transferred prior to the date in which they vest. Dividends and other distributions with respect to Sponsor Vesting Shares shall be set aside by the Company and shall be paid to the Sponsor upon the vesting of such Sponsor Vesting Shares. The Company evaluated the earnout liability under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”) , and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, there are contingent exercise provisions and settlement provisions that exist. Holders may receive differing amounts of shares depending on the company’s stock price or the price paid in a change of control. All remaining shares would be issuable (or the forfeiture provisions would lapse) upon any change of control involving the Company and all remaining shares would be issuable (or the forfeiture provisions would lapse) upon a bankruptcy or insolvency of the company. This means that settlement is not solely impacted by the share price of the Company (that is, the share price observed in or implied by a qualifying change-in-control event), but also by the occurrence of a qualifying change-in-control event. This causes the arrangement to not be indexed to the Company’s own shares and liability classification is appropriate. The Company records these instruments as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date. The earnout liability was fair valued using a Monte Carlo open-ended model. The inputs used for the model were a dividend yield of 0% and 0%, volatility of 108% and 70%, and interest rate of 4.04% and 4.08% at December 31, 2023 and 2022, respectively. At December 31, 2023 and 2022 the balance of the earnout liability was $1.8 million and $42.5 million, respectively. A gain of $41.0 million and $85.4 million for the year ended December 31, 2023 and 2022, respectively, was recorded on the consolidated statements of operations and comprehensive income in the change in the fair value of earnout liability. |
Canadian Government Research an
Canadian Government Research and Development Program Liability | 12 Months Ended |
Dec. 31, 2023 | |
Research and Development [Abstract] | |
Canadian Government Research and Development Program Liability | Canadian Government Research and Development Program Liability In April 2019, the Company entered into a contribution agreement related to the research and development and construction associated with the operation of Origin 1 in which the Company will participate in a Canadian government research and development program (the “R&D Agreement”). Pursuant to the R&D Agreement, the Company will receive funding for eligible expenditures incurred through March 31, 2023 up to the lesser of approximately 18.48% of eligible costs and $23.0 million (in Canadian dollars). The funding will be repaid over 15 years after completion of Origin 1, commencing no sooner than the third fiscal year of consecutive revenues from a commercial plant, but no later than March 2028. The maximum amount to be repaid by the Company under the R&D Agreement is 1.25 times the actual funding received, subject to the following repayment ceiling formula. Repayment of the funding will be reduced by 50% if the Company begins construction before December 31, 2024 of one or more commercial plants that operate in Canada, with costs exceeding $500.0 million (in Canadian dollars), and the plants being constructed and operational within 30 months of the final investment decision, as defined in the R&D Agreement. Once begun, repayments will be paid annually by April of each year through March 31, 2037. Payments will be determined by a formula of the funded amount based on the fiscal year gross business revenue, as defined in the R&D Agreement. At December 31, 2023 and 2022, the Company recorded a liability for the amount received of $7.3 million and $7.2 million, respectively, on the consolidated balance sheets in Canadian government research and development program liability. |
Common Stock Warrants
Common Stock Warrants | 12 Months Ended |
Dec. 31, 2023 | |
Common Stock Warrants [Abstract] | |
Common Stock Warrants | Common Stock Warrants As of December 31, 2023 and 2022, there are 35,476,627 warrants outstanding. As part of Artius’s initial public offering, 24,149,960 Public Warrants were sold. The Public Warrants entitle the holder thereof to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustments. The Public Warrants may be exercised only for a whole number of shares of Common Stock. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will expire on June 25, 2026 at 5:00p.m., New York City time, or earlier upon redemption or liquidation. The Public Warrants are listed on the Nasdaq under the symbol “ORGNW.” The Company may redeem the Public Warrants when exercisable, in whole and not in part, at a price of $0.01 per warrant, so long as the Company provides not less than 30 days’ prior written notice of redemption to each warrant holder, and if, and only if, the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date the Company sends the notice of redemption to the warrant holders. Simultaneously with Artius’s initial public offering, Artius consummated a private placement of 11,326,667 Private Placement Warrants with the Sponsor. The Private Placement Warrant is exercisable for one share of Class A Common Stock at a price of $11.50 per share, subject to adjustment. The Private Placement Warrants are identical to the Public Warrants, except that: (1) the Private Placement Warrants and the shares of Class A Common Stock issuable upon exercise of the Private Placement Warrants are not transferable, assignable or salable until the earliest to occur of: (i) 365 days after the date of the Closing; (ii) the first day after the date on which the closing price of the Public Shares (or any successor securities thereto) equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the date of the Closing; or (iii) the date on which Artius completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Artius’s Public Shareholders having the right to exchange their Public Shares (or any successor securities thereto) for cash, securities or other property, subject to certain limited exceptions, (2) the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except if the reference value equals or exceeds $10.00 and is less than $18.00 (as described above), so long as they are held by the initial purchasers or their permitted transferees, and (3) the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will be entitled to registration rights. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable under all redemption scenarios by the Company and exercisable by such holders on the same basis as the Public Warrants. The Company concluded the Public Warrants and Private Placement Warrants, or Common Stock Warrants, meet the definition of a derivative under ASC 815 and are recorded as liabilities. Upon consummation of the Merger, the fair value of the Common Stock Warrants was recorded on the consolidated balance sheets. The fair value of the Common Stock Warrants was remeasured on the December 31, 2023 and 2022 consolidated balance sheets at $1.3 million and $30.9 million, respectively, and a gain of $29.5 million and $22.0 million, respectively, was recorded on the consolidated statements of operations and comprehensive income. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Dec. 31, 2023 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity | Stockholders’ Equity As of December 31, 2023 and 2022, 1,010,000,000 shares, $0.0001 par value per share are authorized, of which, 1,000,000,000 shares are designated as Common Stock and 10,000,000 shares are designated as Preferred Stock. Common Stock Holders of the Common Stock are entitled to dividends when, as, and if, declared by the Board, subject to the rights of the holders of all classes of stock outstanding having priority rights to dividends. As of December 31, 2023, the Company had not declared any dividends. The holder of each share of Common Stock is entitled to one vote. There were 145,706,531 and 143,034,225 shares of Common Stock (including 4,500,000 Sponsor Vesting Shares not indexed to equity) outstanding as of December 31, 2023 and 2022, respectively. Employee Stock Purchase Plan The Company maintains an Employee Stock Purchase Plan (“ESPP”). The ESPP permits participants to purchase shares of our Common Stock with the purchase price of the shares at a price determined by our Board, which shall not be less than 85% of the lower of the fair market value of our Common Stock on the first day of an offering or on the date of purchase. Initially, following adoption of the ESPP, the maximum number of shares of our Common Stock that may be issued under the ESPP was 1,846,710 . The ESPP contains an “evergreen” share reserve feature that automatically increases the number of shares of Common Stock reserved for issuance under the plan on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to the lesser of (1) one percent (1%) of the fully-diluted shares of our Common Stock on December 31st of the preceding calendar year, (2) 3,693,420 of Common Stock, or (3) such lesser number of shares as determined by our Board. As of December 31, 2023, the number of shares available for issuance under the ESPP was 5,639,944. Our Board made the decision not to increase the number of shares of Common Stock reserved for issuance under the ESPP as of January 1, 2024 as no stock has been offered or issued to employees under the ESPP to date. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. Equity Incentive Plans The Company maintains the following equity incentive plans: the 2010 Stock Incentive Plan, the 2020 Equity Incentive Plan, and the 2021 Equity Incentive Plan, each as amended (together, the “Stock Plans”). Upon closing of the Merger, awards under the 2010 Stock Incentive Plan and 2020 Equity Incentive Plan were converted at the Exchange Ratio, which has the meaning set forth in the Merger Agreement, and the 2021 Equity Incentive Plan was adopted and approved. Origin may grant a wide variety of equity securities under the Stock Plans, including incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance-based stock awards, and other awards. The Company has granted incentive stock options, RSU awards, and performance awards under the Stock Plans. Under the Stock Plans, options must be issued at exercise prices no less than the estimated fair value of the stock on the date of grant and are exercisable for a period not exceeding 10 years from the date of grant. Options granted to employees under the Stock Plans generally vest 25% one year from the vesting commencement date and 1/36th per month thereafter, although certain arrangements call for vesting over other periods. Options granted to non-employees under the Stock Plan vest over periods determined by the Board (generally immediate to four years). RSU awards granted to employees under the 2021 Equity Incentive Plan require a service period of three years and generally vest 33.3% annually over the three-year service period. Under the Stock Plans, the fair value of RSU awards and performance-based stock awards are determined to be the grant date closing stock price. For awards with performance-based conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. The performance-based stock awards are subject to vesting based on a performance-based condition and a service-based condition. The performance-based stock awards will vest in a percentage of the target number of shares between 0% and 300%, depending on the extent the performance conditions are achieved. Initially, following adoption of the 2021 Equity Incentive Plan, there were 18,467,109 shares of Common Stock reserved for issuance under the Stock Plans. The 2021 Equity Incentive Plan contains an “evergreen” share reserve feature that automatically increases the number of shares of Common Stock reserved for issuance under the plan on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to five percent (5%) of the fully-diluted Common Stock on December 31 of the preceding year unless our board acts prior to January 1 to increase the share reserve by a lesser amount. The number of shares added to the share reserve on January 1 of a given year is reduced automatically to the extent necessary to avoid causing the share reserve to exceed fifteen percent (15%) of the fully-diluted Common Stock on December 31 of the preceding year. As of December 31, 2023, the number of shares available for issuance under the 2021 Equity Incentive Plan was 28,761,816, and there were 10,244,412 shares available for grant. On January 1, 2024, the number of shares of Common Stock reserved for issuance under the 2021 Equity Incentive Plan was automatically increased by 1,242,387 shares pursuant to the 2021 Plan’s “evergreen” provision to a total of 30,004,203 shares. The following tables summarize stock option activity under the Stock Plans: Outstanding Options Weighted Weighted Average Aggregate intrinsic value (in thousands) Balance as of December 31, 2022 6,471,062 $ 0.17 7.29 Granted — — Exercised (959,143) 0.15 Forfeited / canceled (33,909) 0.14 Balance as of December 31, 2023 5,478,010 $ 0.17 6.05 Vested and expected to vest at December 31, 2023 5,478,010 $ 0.17 6.05 $ 3,638 Vested and exercisable at December 31, 2023 3,501,925 $ 0.19 5.62 $ 2,263 During the years ended December 31, 2023 and 2022, the Company did not grant any stock options. As of December 31, 2023, there were 3,501,925 options exercisable. The total intrinsic value of the options exercised during the year ended December 31, 2023 and 2022 was $2.5 million and $8.5 million, respectively. The intrinsic value of options exercised during each fiscal year is calculated as the difference between the market value of the stock at the time of exercise and the exercise price of the stock option. As of December 31, 2023, the Company had stock-based compensation of $1.7 million, related to unvested stock options not yet recognized that is expected to be recognized over an estimated weighted average period of 0.8 years. The Company issued 2,920,732 of performance and market-based stock options during 2020. During the quarter ended March 31, 2021, the Company modified the vesting schedule of 529,119 of these performance and market-based stock options such that vesting of 1/48th per month would commence upon signing of the Business Combination. The Company entered into the Merger Agreement on February 16, 2021 resulting in the commencement of expense recognition related to these 529,119 options during the quarter ended March 31, 2021. For the remaining 2,391,613 performance and market-based stock options, expense commenced on the close date of the Merger, June 25, 2021, as that is the date when the performance condition was achieved. The following table summarizes the RSU award and performance-based stock award activity: Outstanding Weighted-average grant date fair value Unvested balance at December 31, 2022 6,371,950 $ 6.24 Granted - RSU awards 9,374,125 1.19 Granted - performance-based stock awards 455,368 0.93 RSU awards vested and converted to shares (1,919,853) 5.49 Vested - performance-based stock awards — — Forfeited - RSU awards (680,036) 4.89 Forfeited - performance-based stock awards (555,450) 6.81 Unvested balance at December 31, 2023 13,046,104 $ 2.54 Expected to vest 10,927,261 The RSU awards entitle the holder upon vesting to be issued on a future date the number of shares of Common S tock that is equal to the number of restricted stock units subject to the RSU awards. The total fair value of shares vested during the year ended December 31, 2023 and 2022 was $2.7 million and $3.6 million, respectively. The number of RSU awards vested during 2023 totaled 1,919,853, of which the issuance of 165,956 common shares has been deferred at the election of the participant. The common shares for the deferred RSUs will be released sixty days following the participant's departure from the Company. The common shares for an additional 40,734 RSU awards vested during 2023 will be issued in 2024. The Company issued 455,368 performance-based stock awards during 2023. During the year ended December 31, 2023, the performance conditions for all of the outstanding performance-based stock awards were not probable of being met, therefore no performance award stock compensation has been recorded. During the year ended December 31, 2022, one performance condition for the granted performance-based stock awards was met, therefore performance-based award stock compensation of $2.8 million was recorded. As of December 31, 2023, there were 1,202,434 unvested performance-based awards subject to certain performance criteria for vesting. The vesting period for RSU awards is generally three years. Total remaining compensation expense for RSU awards to be recognized under the 2021 Equity Incentive Plan is $19.3 million as of December 31, 2023, and will be amortized on a straight-line basis over an estimated weighted average period of 2.2 years. The maximum amount of stock-based compensation expense for the unvested performance-based stock awards, assuming maximum performance, is $11.4 million. Total remaining compensation expense for performance-based stock awards will be recognized over the requisite service periods once the performance-based conditions are deemed to be probable. The Company effected a workforce reduction in November 2023 of which approximately 30% of total employees were impacted. This reduction, as part of our organizational realignment, reflects the deferral of research programs with longer-term economic impacts and the acceleration of higher-margin revenue opportunities. The Board authorized certain changes to the stock-based awards in connection with the workforce reduction plan to allow accelerated vesting of a portion of affected employees’ unvested equity awards. The Company recorded a total workforce reduction charge of $0.2 million in the fourth quarter of 2023. The charge consists of severance and benefits costs, inclusive of cash expenditures for employee separation costs of $0.5 million and non-cash charges of $(0.3) million for stock based compensation expense. $0.4 million associated with the modification of certain equity awards, offset by $(0.7) million related to equity awards forfeited by the affected employees. The cash expenditures and non-cash stock based compensation expense for employee separation costs was recorded in general and administrative and research and development expenses on the consolidated statements of operations and comprehensive income and a portion was capitalized within construction in progress on the consolidated balance sheets. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Income before income tax expenses consisted of the following for the year ended: (in thousands) December 31, 2023 December 31, 2022 United States $ 22,481 $ 81,269 Foreign 230 (2,700) Income before income tax expenses $ 22,711 $ 78,569 The federal, state, and foreign income and deferred tax expenses are summarized as follows for the year ended: (in thousands) December 31, 2023 December 31, 2022 Current Federal $ — $ — State 20 3 Foreign 139 — Total current tax expenses $ 159 $ 3 Deferred Federal $ — $ — State — — Foreign (1,246) — Total deferred tax benefits $ (1,246) $ — Total tax expenses $ (1,087) $ 3 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company’s deferred taxes are as follows for the year ended: (in thousands) December 31, 2023 December 31, 2022 Deferred tax assets Net operating loss carryforwards $ 34,076 $ 27,210 Available for sale marketable securities 825 2,064 Lease liabilities 1,050 532 Other 51 36 Fixed assets and intangibles 445 25 Capitalized research and development costs 4,456 1,929 Stock Compensation 2,806 1,544 Total deferred tax assets $ 43,709 $ 33,340 Deferred tax liabilities ROU asset $ (1,012) $ (515) Other (16) — Fixed assets and intangibles — (479) Total deferred tax liabilities $ (1,028) $ (994) Valuation allowance $ (41,420) $ (32,346) Net deferred taxes $ 1,261 $ — ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is more likely than not. Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Regarding the Origin US entities, the Company is in a significant cumulative loss position and has provided a valuation allowance against the US net deferred tax assets. Origin Canada is recognizing income and is projecting future taxable income sufficient to offset all its deferred tax assets. Therefore, some of the deferred tax assets in Canada are being recognized in 2023. The valuation allowance increased by $9.1 million and $6.7 million for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023, we had federal net operating loss carryforwards of approximately $139.7 million to offset future federal taxable income, with $42.0 million available through 2037 and $97.7 million available indefinitely. We have state net operating loss carryforward of $42.8 million, available through 2043. We had foreign net operating loss carryforwards of approximately $7.2 million that may offset future foreign taxable income through 2043. At December 31, 2023, the Company has research and experimentation credit carryforwards of $0.03 million for foreign tax purposes that expire after 2038. The Company plans to evaluate its R&D credits in the future and amend prior year federal an California tax returns to claim credits, which will carryforward to offset future income tax liability. The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows for the year ended: December 31, 2023 December 31, 2022 Statutory rate 21.0 % 21.0 % State tax (12.2) 1.1 Foreign tax 0.6 — Warrants and other equity items (65.3) (28.7) Valuation allowance 46.8 6.4 Other 0.5 0.7 Foreign rate differential 0.6 (0.2) Stock-based compensation 3.2 (0.3) Total (4.8) % — % The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows for the year ended: December 31, 2023 December 31, 2022 Statutory rate $ 4,769 $ 16,500 State tax (2,761) 875 Foreign tax 139 — Warrants and other equity items (14,808) (22,559) Valuation allowance 10,629 5,040 Other 98 502 Foreign rate differential 128 (148) Stock-based compensation 719 (207) Total $ (1,087) $ 3 Under certain provisions of the Internal Revenue Code of 1986, as amended, a portion of the federal and state net operating loss carryforwards may be subject to an annual utilization limitation as a result of a change in ownership of the Company. Federal and California tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (“Section 382”). The Company has experienced ownership changes as defined by IRC Section 382 and the impact of those changes has been reflected in the consolidated financial statements. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes. There were no unrecognized tax benefits in the years ended December 31, 2023 and 2022. The Company files income tax returns in the United States, various US states, and Canada. All tax years remain open in all jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other foreign jurisdictions. The Company does not anticipate any significant changes within 12 months of this reporting date of its uncertain tax positions. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Leases | Leases The Company leases office space and research and development space in Sacramento, California and Sarnia, Ontario under non-cancelable lease agreements and leases various office equipment, and warehouse space. Certain operating leases contain options to extend the lease. The Company included the periods covered by these options as we are reasonably certain to exercise the options for all leases. For leases with the option to extend on a month-to-month basis after the defined extension periods, the Company is reasonably certain to extend for the same term as related leases. As such, lease terms for all leased assets located at the same locations have the same end dates. Rent deposits relating to leases are included within other long-term assets on the consolidated balance sheets. Variable lease costs include operating expenses for the shared common area, and the amount is based on an annual estimate of the actual common area expenses from the preceding year and are payable monthly. Certain leases were extended during the period ended September 30, 2023. The lease modifications were not accounted for as a separate contract and we remeasured our lease liabilities and ROU assets on the modification date. Our operating leases have remaining lease terms of one The Company elected the accounting policy election to account for lease and nonlease components as a single lease component for all asset classes. Further, the Company elects to recognize lease payments on short-term leases in profit or loss on a straight-line basis over the lease term for all asset classes, excluding such leases from recognition requirements under ASC 842. The components of lease cost were as follows for the year ended: (in thousands) December 31, 2023 December 31, 2022 Operating lease cost $ 807 $ 671 Variable lease cost 109 107 Total lease cost $ 916 $ 778 Other information related to leases is as follows: (in thousands) December 31, 2023 December 31, 2022 Operating lease ROU asset $ 4,468 $ 2,779 Weighted average remaining lease term (in years): Operating leases 9.49 5.28 Weighted average discount rate: Operating leases 7.4 % 3.4 % (in thousands) December 31, 2023 December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 726 $ 572 Operating lease ROU assets obtained in exchange for lease obligations $ 2,308 $ 1,687 To calculate the ROU assets and lease liabilities, the Company uses the discount rate implicit in lease agreements when available. When the implicit discount rates are not readily determinable, the Company uses the incremental borrowing rate, determined as of the later of the date of adoption for ASC 842, date of lease inception or date of lease modification. This rate is determined for individual leases based on available information regarding jurisdiction, lease term, and asset class. Further, the interest environment was considered, including analysis of benchmark rates from promissory notes, credit curve yields for bonds, and synthetic curves based on discount margin spreads. Maturities of operating lease liabilities as of December 31, 2023 were as follows: (in thousands) December 31 2024 $ 687 2025 636 2026 607 2027 595 2028 612 Thereafter 3,348 Total lease payments 6,485 Less: imputed interest (1,911) Less: operating lease liabilities, current (367) Operating lease liabilities, non-current $ 4,207 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Commitments In connection with the closing of the Merger, the Company entered into the Investor Rights Agreement on June 25, 2021 (the “Investor Rights Agreement”), pursuant to which the holders of Registrable Securities (as defined therein) became entitled to, among other things, customary registration rights, including demand, piggy-back and shelf registration rights. The Investor Rights Agreement also provides that the Company will pay certain expenses relating to such registrations and indemnify the registration rights holders against (or make contributions in respect of) certain liabilities which may arise under the Securities Act. On July 15, 2021, the Company registered the Registrable Securities for resale pursuant to a Registration Statement on Form S-1, as amended (File No. 333-257931), which became effective on July 30, 2021. The Company filed Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 on Form S-3 (File No. 333-257931), which became effective on August 8, 2022. In May 2018, the Company executed the agreements for certain services, to facilitate the development and thus bring Origin 1 to the condition necessary for its intended use, commencing in different periods between July 2018 and September 2019, and all generally for five years periods. The agreements are generally automatically extended for one year periods thereafter. The agreements include annual fixed payments subject to escalation clauses at the beginning of each calendar year, as defined in the agreement. The minimum fixed payments are $0.4 million per year over the fixed term. Certain of the agreements include quantities that are based on volumes, as defined in the applicable agreements. The Company is also responsible for applicable taxes under these agreements. The total amount capitalized into property, plant and equipment, net under the agreement was $0.6 million and $1.5 million during the year ended December 31, 2023 and 2022, respectively. In April 2023, the Company entered into an agreement for conversion of materials produced by Origin 1 into certain derivatives. Pursuant to the agreement, the Company agreed to purchase conversion services for a certain minimum quantity of product on a take-or-pay basis for a term of 5 years beginning in 2025 for an aggregate total cost of $33.0 million. Accordingly the Company is obligated to purchase not less than $5.0 million during 2025 and a minimum of $7.0 million each of 2026 through 2029. The Company made advance payments totaling $11.5 million to the counterparty as of December 31, 2023, which is included in the foregoing aggregate total, and the agreement provides for the Company to be fully reimbursed for the advance payments in the form of a discount on conversion services over the term. The agreement gives the Company the right, but not the obligation, to purchase conversion services for an additional quantity of product in 2024 and stipulates a reduction in the take-or-pay commitment under certain circumstances including the counterparty’s inability to meet the required product specification. The agreement automatically renews for an additional year unless either party gives advance notice of an intention not to renew. In addition, either party may terminate the agreement in the event of the other party’s insolvency or breach of a material term. The Company recorded the advance payments as other long-term assets on the consolidated balance sheets. In February 2023, the Company entered into a nonexclusive patent license agreement for use in connection with production at a specific licensed facility. The license expires upon cessation of production at that facility. The Company made a nonrefundable $5.0 million deposit in 2022 toward securing the license and, as a result of signing the license agreement, made an additional nonrefundable payment of $7.9 million during 2023 and may make additional payments depending on the achievement of certain milestones. The total payment is included in other long-term assets. In connection with this license, the Company entered into a conditional offtake agreement under which the licensor will supply the Company with a certain amount of the same type of products to be produced at the licensed facility in order to accelerate market development for these products and related applications. In July 2017, the Company entered into a nonexclusive patent license agreement for $0.1 million, which expires upon expiration of the last to expire of the licensed patents. Under this agreement, the Company will pay less than $0.1 million minimum royalty payments per year and, if the Company develops and sells certain products based on the licensed patents. Certain products that Origin is currently developing and anticipates selling are expected to utilize these patents. In December 2016, the Company entered into a patent license agreement for $0.5 million, which expires upon expiration of the last to expire of the licensed patents. Under this agreement, if the Company develops and sells specific products based on the patents, the Company would pay a royalty up to a cumulative $0.5 million from Origin 1, whereby no further payments will be due for any production at Origin 1. If production of those products occurs at subsequent facilities, the Company will pay an upfront license fee royalty and a variable royalty based on production at that subsequent facility, capped at an aggregate $10 million per facility. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the year ended December 31, 2023 and 2022. In November 2016, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the patent. Under this agreement, if the Company produces products based on the patent, the Company will pay an annual royalty upon commencement of operations on Origin 1 which will not exceed $1.0 million cumulatively. The pipeline of Company products and sales are not currently expected to be subject to this patent. The annual royalty payments are less than $0.1 million. In September 2011, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the patent. Under this agreement, if the Company develops and sells specific products based on the patent, the Company would pay a royalty up to $2.0 million per year and $10.0 million in the aggregate. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the year ended December 31, 2023 and 2022. In June 2011, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the licensed patent. Under this agreement, the Company pays less than $0.1 million royalty fee annually and if the Company develops and sells specific products based on the patent, 0.4% of net sales. The pipeline of Company products and sales are not currently expected to be subject to this patent. We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work. Contingencies At times there may be claims and legal proceedings generally incidental to the normal course of business that are pending or threatened against the Company. For instance, in August 2023, a shareholder filed a putative securities class action complaint in the Eastern District of California against the Company and certain of its officers, alleging violations of the federal securities laws. An additional complaint, alleging the same claims against the same defendants, was filed in October 2023. Both cases allege a class period of February 23, 2023 to August 9, 2023, and seek as relief, among other things, unspecified damages and fees and costs. The two cases have since been consolidated into In re Origin Materials, Inc. Sec. Litig. , No. 2:23-cv-01816-WBS-JDP (E.D. Cal.). A lead plaintiff was appointed for the consolidated case on December 14, 2023 and filed an amended complaint on March 1, 2024. At this preliminary stage in the litigation, the Company cannot predict any particular outcome or financial impact thereof, if any. |
Basic and Diluted Net Income Pe
Basic and Diluted Net Income Per Share | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Basic and Diluted Net Income Per Share | Basic and Diluted Net Income Per Share The following table sets forth the computation of basic and diluted net income per share attributable to common stockholders. Basic net income per share is computed by dividing net income for the period by the weighted-average number of common shares outstanding during the period, which excludes Sponsor Vesting Shares which are legally outstanding, but subject to return to the Company. Diluted net income per share is computed by dividing net income for the period by the weighted-average common shares outstanding during the period, plus the dilutive effect of the stock options and RSU awards, as applicable pursuant to the treasury stock method. The following table sets forth the computation of basic and diluted net income per share: (In thousands, except for share and per share amounts) Year Ended December 31, 2023 2022 Numerator: Net income attributable to common stockholders—Basic $ 23,798 $ 78,569 Net income attributable to common stockholders—Diluted $ 23,798 $ 78,569 Denominator: Weighted-average common shares outstanding—Basic (1) 139,718,385 137,563,877 Stock options 2,872,491 4,571,301 RSU awards 67,547 11,589 Weighted-average common shares outstanding—Diluted (1) 142,658,423 142,146,767 Net income per share—Basic $ 0.17 $ 0.57 Net income per share—Diluted $ 0.17 $ 0.55 (1) Excludes weighted-average Sponsor Vesting Shares subject to return of 4,500,000 shares for the year ended December 31, 2023 and 2022. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The following potentially dilutive securities for common stock were outstanding and excluded from diluted earnings per share as they are subject to performance or market conditions that were not probable of being achieved as follows: Year Ended December 31, 2023 2022 Options to purchase common stock 1,481,531 1,481,531 Performance-based stock awards 2,018,934 2,218,925 Earnout shares 25,000,000 25,000,000 Sponsor vesting shares 4,500,000 4,500,000 The following outstanding shares of out-of-the-money options and potentially dilutive warrants were excluded from the computation of diluted net income per sha re attributable to common stockholders for the periods presented because including them would have been antidilutive: Year Ended December 31, 2023 2022 Options to purchase common stock 41,357 — Warrants to purchase common stock 35,476,667 35,476,667 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Pay vs Performance Disclosure | ||
Net income | $ 23,798 | $ 78,569 |
Insider Trading Arrangements
Insider Trading Arrangements shares in Millions | 3 Months Ended | 12 Months Ended |
Dec. 31, 2023 shares | Dec. 31, 2023 shares | |
Trading Arrangements, by Individual | ||
Non-Rule 10b5-1 Arrangement Adopted | false | |
Rule 10b5-1 Arrangement Terminated | false | |
Non-Rule 10b5-1 Arrangement Terminated | false | |
Rich Riley [Member] | ||
Trading Arrangements, by Individual | ||
Material Terms of Trading Arrangement | Rich Riley, Co-CEO and Director, entered into a prearranged stock trading plan on December 15, 2023. Mr. Riley’s plan provides for the sale of up to 600,000 shares of the Company’s common stock between March 15, 2024 and December 31, 2024. This trading plan was entered into during an open trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in the Company’s securities. | |
Name | Rich Riley | |
Title | Co-CEO and Director | |
Rule 10b5-1 Arrangement Adopted | true | |
Adoption Date | December 15, 2023 | |
Arrangement Duration | 291 days | |
Aggregate Available | 0.6 | 0.6 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). |
Use of Estimates | Use of Estimates |
Principles of Consolidation | Principles of Consolidation |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents, marketable securities and accounts receivable. The Company maintains its cash, cash equivalents, and marketable securities accounts with financial institutions where, at times, deposits exceed federal insurance limits. Management believes that the Company is not currently exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. While the Company has not experienced losses of these deposits to date, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected. For accounts receivable, as of December 31, 2023, our top two customers from product sales, in the aggregate, accounted for approximately 67% of total accounts receivable outstanding balances and accounted for approximately 77% of total revenue for the year ended December 31, 2023. |
Cash and Cash Equivalents and Restricted Cash | Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts. |
Marketable Securities | Marketable Securities The Company’s investment policy requires the Company to purchase investments that are consistent with the classification of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component in the consolidated statements of operations and comprehensive income until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses. Expected credit losses on securities are recognized in other income, net in the consolidated statements of operations and comprehensive income, and any remaining unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss in the consolidated statements of stockholders’ equity. For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Amortization of discounts and premiums, net, and interest on securities classified as available for sale are included as a component of interest income within other income (expenses). The nature of these financial instruments include instruments for which quoted prices are available but traded less frequently, instruments whose fair value has been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data, and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 2 financial instruments include agency mortgage-backed securities, corporate fixed income securities infrequently traded, and other securities, which primarily consist of sovereign debt, U.S. government agency securities, loans, and state and municipal securities. |
Derivative Financial Instruments | Derivative Financial Instruments The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the consolidated balance sheets. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3). Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market. The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. |
Accounts Receivable and unbilled services, net | Accounts Receivable and unbilled services, net |
Other Receivables | Other Receivables |
Inventory | Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using a weighted-average cost approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value. |
Property, Plant, and Equipment | Property, Plant, and Equipment Land is non-amortizing. Computer equipment and software includes an immaterial amount of internal use software. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to expenses. |
Intangible Assets | Intangible Assets |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets |
Common Stock Warrants Liability | Common Stock Warrants Liability The Company assumed 24,149,960 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Common Stock Warrants” or “Warrants”) upon the Merger, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A common stock at an exercise price of at $11.50 per share. As of December 31, 2023, 24,149,960 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the Public Warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants. There were no Private Placement Warrants that became Public Warrants as of Dec 31, 2023. The Company evaluated the Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”) |
Earnout Liability | Earnout Liability |
Leases | Leases We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a finance lease. The Company has leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC 842, Leases . The Company recognizes a right-of-use (“ROU”) asset and lease liability for leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain to be exercised. |
Revenue Recognition | Revenue Recognition The Company began to recognize revenue in 2023. Our revenues are from product sales and service agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct—that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) . The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or service to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and service agreements, we perform the following steps: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations; and 5. Recognizing revenue when, or as, the performance obligations are satisfied. We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer. Our service agreements are customized, specified, and often include various stages at which transaction prices are agreed to. These service agreements often include multiple performance obligations within each stage. We identify each performance obligation at contract inception and allocate the consideration to each distinct performance obligation based on the stand-alone selling price of each performance obligation. Our services are tailored to each individual customer and the stand-alone selling prices are not directly observable. As our service agreements include customers that are not in similar geographic markets and for different services, therefore the Company uses the expected cost plus margin approach to estimate the stand-alone selling price for each of our performance obligations. We recognize revenue from the service agreements over the period during which the services are performed and recognize the associated costs as they are incurred. In general, we recognize revenue when, or as, our performance obligations under the terms of a contract with our customer are satisfied. For product sales, this happens when we transfer control of our products and risk of loss to the customer or when title passes upon shipment. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring our products. Taxes collected from customers and remitted to governmental authorities are excluded from revenues. The Company recognizes its revenue from direct product sales which is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. For service agreements, the timing of satisfying performance obligations may differ from the timing of the invoicing of customers and the receipt of customer payments. The Company records a receivable prior to payment if there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records contract liability (deferred income) until the performance obligations are satisfied. Revenue is recorded in an amount that reflects that consideration we expect to be entitled to in exchange for those goods or services. We have elected to treat shipping and handling activities as fulfillment costs. Cost of revenues Cost of revenues for product sales consists primarily of cost associated with the purchase of finished goods. Cost of revenues for service agreements is based on the actual cost incurred, which mainly consists of the direct cost from vendors and overhead costs such as payroll and benefit related to our employees who provide the services to customers. |
Research and Development Cost | Research and Development Cost |
Stock-Based Compensation | Stock-Based Compensation The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. In addition, the Company capitalizes stock-based compensation related to employees whose costs are necessary to bring the asset to its intended use. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including: • Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term. • Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor. • Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future. • Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate. • Risk-free interest rate |
Workforce Reduction Costs | Workforce Reduction Costs In November 2023, we announced a plan for a workforce reduction of approximately 30% of our total workforce to realign and optimize our workforce requirements in alignment with our refined corporate strategy. The Company aims to focus on cash conservation and affected an organizational realignment to reflect the deferral of research programs with longer-term economic impacts and the acceleration of higher margin revenue opportunities. Workforce reduction costs primarily consisted of severance and benefits costs associated with the workforce reduction in November 2023 (see Note 15). As of December 31, 2023, we do not expect to record any significant future charges related to the workforce reduction plan. |
Income Taxes | Income Taxes Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely. |
Functional Currency Translation | Functional Currency Translation |
Comprehensive Income (Loss) | Comprehensive Income (Loss) |
Basic and Diluted Net Income Per Share | Basic and Diluted Net Income Per Share Basic net income per common share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive |
Reclassifications | Reclassifications |
Segment Reporting | Segment Reporting |
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted | Recently Adopted Accounting Pronouncements In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (“Topic 815”). This update clarifies the guidance in Topic 815 on fair value hedge accounting of interest rate risk for portfolios and financial assets. Among other things, the amended guidance established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible and renamed that method the “portfolio layer” method. ASU 2022-01 is effective January 1, 2023. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (“Topic 280”) - Improvements to Reportable Segment Disclosures , which updates disclosures about a public entity’s reportable segments, including more detailed information about a reportable segment’s expenses. The amendments in this update require that we disclose (i) on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss (collectively referred to as the “significant expense principle”), (ii) on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition. The other segment items category is the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each reported measure of segment profit or loss, (iii) annual disclosures about a reportable segment’s profit or loss and assets currently required by Topic 280 in interim periods, (iv) clarify that if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources, we may report one or more of those additional measures of segment profit. However, at least one of the reported segment profit or loss measures (or the single reported measure, if only one is disclosed) should be the measure that is most consistent with the measurement principles used in measuring the corresponding amounts in the public entity’s consolidated financial statements, (v) the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (vi) requires that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. This guidance is required to be applied retrospectively to all prior periods presented in the financial statements. This guidance is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements, other than additional disclosures in our notes to the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (“Topic 740”) - Improvements to Income Tax Disclosures, to provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The amendments in this update require that on an annual basis we (i) disclose specific categories in the rate reconciliation, (ii) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate), (iii) disclose additional information about income taxes paid and expensed disaggregated by federal, state, and foreign taxes, and (iv) disclose income (loss) from continuing operations before income tax expense disaggregated between domestic and foreign. The guidance should be applied on a prospective basis however a retrospective application is permitted. The guidance is effective for the Company for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements, other than additional disclosures in our notes to the consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Cash, Cash Equivalents, and Restricted Cash | Cash, cash equivalents, and restricted cash consisted of the following (in thousands): December 31, 2023 December 31, 2022 Cash and cash equivalents $ 75,502 $ 107,858 Restricted cash — 490 Total cash, cash equivalents, and restricted cash $ 75,502 $ 108,348 |
Schedule of Allowance for Credit Loss | December 31, 2023 December 31, 2022 Accounts receivable, gross $ 15,204 $ — Allowance for credit loss — — Unbilled receivable 924 — Accounts receivable, net $ 16,128 $ — |
Schedule of Estimated Useful Lives of Assets | The estimated useful lives of assets are as follows: Computer equipment and software 3 years Lab equipment 5 years Furniture, fixtures, and machinery 5 years Land improvements and infrastructure 20 years Manufacturing equipment and pilot plant 25 years Buildings 40 years |
Fair Value Measurement (Tables)
Fair Value Measurement (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Summary of Assets and Liabilities Measured at Fair Value | The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows: Fair Value as of December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 75,502 $ — $ — $ 75,502 Marketable securities — 82,761 — 82,761 Total fair value $ 75,502 $ 82,761 $ — $ 158,263 Liabilities: Common stock warrants (Public) $ 913 $ — $ — $ 913 Common stock warrants (Private Placement) — 428 — 428 Earnout liability — — 1,783 1,783 Derivative liability — 300 — 300 Total fair value $ 913 $ 728 $ 1,783 $ 3,424 Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 108,348 $ — $ — $ 108,348 Marketable securities — 215,464 — 215,464 Total fair value $ 108,348 $ 215,464 $ — $ 323,812 Liabilities: Common stock warrants (Public) $ 21,015 $ — $ — $ 21,015 Common stock warrants (Private Placement) — 9,856 — 9,856 Earnout liability — — 42,533 42,533 Derivative liability — 344 — 344 Total fair value $ 21,015 $ 10,200 $ 42,533 $ 73,748 |
Summary of Activities of Earnout Liability | The following table summarized the activities for the earnout liability: December 31, 2023 December 31, 2022 Balance at beginning of period $ 42,533 $ 127,757 Changes in fair value of earnout liability (40,983) (85,437) Other 233 213 Balance at end of period $ 1,783 $ 42,533 |
Schedule of Marketable Securities | The Company’s marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. Amortized cost net of unrealized gain (loss) is equal to fair value. The following table summarized the marketable securities by major security type as follows: As of December 31, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 21,869 $ 26 $ (847) $ 21,048 Asset-backed securities 52,199 26 (2,289) 49,936 U.S. government and agency securities 11,706 — (270) 11,436 Foreign government and agency securities 372 — (31) 341 Total marketable securities $ 86,146 $ 52 $ (3,437) $ 82,761 As of December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 17,568 $ 38 $ — $ 17,606 Corporate bonds 115,134 — (4,923) 110,211 Asset-backed securities 70,825 8 (3,885) 66,948 U.S. government and agency securities 19,308 — (917) 18,391 Foreign government and agency securities 375 — (37) 338 Municipal/provincial bonds and other 2,000 — (30) 1,970 Total marketable securities $ 225,210 $ 46 $ (9,792) $ 215,464 |
Schedule of Marketable Security Contractual Maturities | The contractual maturities of the investments classified as marketable securities are as follows: As of December 31, 2023 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Corporate bonds $ 20,756 $ 292 $ — $ 21,048 Asset-backed securities 238 1,806 47,892 49,936 U.S. government and agency securities 8,929 — 2,507 11,436 Foreign government and agency securities 341 — — 341 Total marketable securities $ 30,264 $ 2,098 $ 50,399 $ 82,761 As of December 31, 2022 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Commercial paper $ 17,606 $ — $ — $ 17,606 Corporate bonds 74,797 35,414 — 110,211 Asset-backed securities 1,907 4,833 60,207 66,947 U.S. government and agency securities 7,719 7,480 3,192 18,391 Foreign government and agency securities — 338 — 338 Municipal/provincial bonds and other 1,971 — — 1,971 Total marketable securities $ 104,000 $ 48,065 $ 63,399 $ 215,464 |
Property, Plant and Equipment (
Property, Plant and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property Plant and Equipment | Property, plant, and equipment consisted of the following: (in thousands) Estimated useful lives December 31, 2023 December 31, 2022 Land $ 11,356 $ 11,358 Land improvements and infrastructure 20 years 62,930 — Manufacturing equipment and pilot plant 25 years 116,754 4,599 Computer equipment and software 3 years 1,629 598 Lab equipment 5 years 3,468 2,526 Furniture, fixtures, and machinery 5 years 1,094 948 Total 197,231 20,029 Less accumulated depreciation and amortization (8,136) (4,693) Construction in process 54,023 138,847 Total property, plant, and equipment, net $ 243,118 $ 154,183 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Finite-Lived Intangible Assets | Intangible assets consisted of the following: (in thousands) December 31, 2023 December 31, 2022 Patents $ 413 $ 404 Less accumulated amortization (292) (244) Total intangible assets $ 121 $ 160 |
Inventory (Tables)
Inventory (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventory balances consist of the following: (in thousands) December 31, 2023 December 31, 2022 Finished goods $ 24 $ — Raw materials 888 — Total $ 912 $ — |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Stockholders' Equity Note [Abstract] | |
Summary of Stock Option Activity | The following tables summarize stock option activity under the Stock Plans: Outstanding Options Weighted Weighted Average Aggregate intrinsic value (in thousands) Balance as of December 31, 2022 6,471,062 $ 0.17 7.29 Granted — — Exercised (959,143) 0.15 Forfeited / canceled (33,909) 0.14 Balance as of December 31, 2023 5,478,010 $ 0.17 6.05 Vested and expected to vest at December 31, 2023 5,478,010 $ 0.17 6.05 $ 3,638 Vested and exercisable at December 31, 2023 3,501,925 $ 0.19 5.62 $ 2,263 |
Schedule of RSU and Performance Award Activity | The following table summarizes the RSU award and performance-based stock award activity: Outstanding Weighted-average grant date fair value Unvested balance at December 31, 2022 6,371,950 $ 6.24 Granted - RSU awards 9,374,125 1.19 Granted - performance-based stock awards 455,368 0.93 RSU awards vested and converted to shares (1,919,853) 5.49 Vested - performance-based stock awards — — Forfeited - RSU awards (680,036) 4.89 Forfeited - performance-based stock awards (555,450) 6.81 Unvested balance at December 31, 2023 13,046,104 $ 2.54 Expected to vest 10,927,261 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income before Provision for Income Tax | Income before income tax expenses consisted of the following for the year ended: (in thousands) December 31, 2023 December 31, 2022 United States $ 22,481 $ 81,269 Foreign 230 (2,700) Income before income tax expenses $ 22,711 $ 78,569 |
Schedule of Federal and State Income Tax Expense | The federal, state, and foreign income and deferred tax expenses are summarized as follows for the year ended: (in thousands) December 31, 2023 December 31, 2022 Current Federal $ — $ — State 20 3 Foreign 139 — Total current tax expenses $ 159 $ 3 Deferred Federal $ — $ — State — — Foreign (1,246) — Total deferred tax benefits $ (1,246) $ — Total tax expenses $ (1,087) $ 3 |
Schedule of Deferred Tax Assets and Liabilities | The tax effects of significant items comprising the Company’s deferred taxes are as follows for the year ended: (in thousands) December 31, 2023 December 31, 2022 Deferred tax assets Net operating loss carryforwards $ 34,076 $ 27,210 Available for sale marketable securities 825 2,064 Lease liabilities 1,050 532 Other 51 36 Fixed assets and intangibles 445 25 Capitalized research and development costs 4,456 1,929 Stock Compensation 2,806 1,544 Total deferred tax assets $ 43,709 $ 33,340 Deferred tax liabilities ROU asset $ (1,012) $ (515) Other (16) — Fixed assets and intangibles — (479) Total deferred tax liabilities $ (1,028) $ (994) Valuation allowance $ (41,420) $ (32,346) Net deferred taxes $ 1,261 $ — |
Schedule of Effective Tax Rate | The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows for the year ended: December 31, 2023 December 31, 2022 Statutory rate 21.0 % 21.0 % State tax (12.2) 1.1 Foreign tax 0.6 — Warrants and other equity items (65.3) (28.7) Valuation allowance 46.8 6.4 Other 0.5 0.7 Foreign rate differential 0.6 (0.2) Stock-based compensation 3.2 (0.3) Total (4.8) % — % The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows for the year ended: December 31, 2023 December 31, 2022 Statutory rate $ 4,769 $ 16,500 State tax (2,761) 875 Foreign tax 139 — Warrants and other equity items (14,808) (22,559) Valuation allowance 10,629 5,040 Other 98 502 Foreign rate differential 128 (148) Stock-based compensation 719 (207) Total $ (1,087) $ 3 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Components of Lease Cost and Other Information | The components of lease cost were as follows for the year ended: (in thousands) December 31, 2023 December 31, 2022 Operating lease cost $ 807 $ 671 Variable lease cost 109 107 Total lease cost $ 916 $ 778 Other information related to leases is as follows: (in thousands) December 31, 2023 December 31, 2022 Operating lease ROU asset $ 4,468 $ 2,779 Weighted average remaining lease term (in years): Operating leases 9.49 5.28 Weighted average discount rate: Operating leases 7.4 % 3.4 % (in thousands) December 31, 2023 December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 726 $ 572 Operating lease ROU assets obtained in exchange for lease obligations $ 2,308 $ 1,687 |
Operating Lease Maturity | Maturities of operating lease liabilities as of December 31, 2023 were as follows: (in thousands) December 31 2024 $ 687 2025 636 2026 607 2027 595 2028 612 Thereafter 3,348 Total lease payments 6,485 Less: imputed interest (1,911) Less: operating lease liabilities, current (367) Operating lease liabilities, non-current $ 4,207 |
Basic and Diluted Net Income _2
Basic and Diluted Net Income Per Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Summary of Basic and Diluted Loss per Ordinary Share | The following table sets forth the computation of basic and diluted net income per share: (In thousands, except for share and per share amounts) Year Ended December 31, 2023 2022 Numerator: Net income attributable to common stockholders—Basic $ 23,798 $ 78,569 Net income attributable to common stockholders—Diluted $ 23,798 $ 78,569 Denominator: Weighted-average common shares outstanding—Basic (1) 139,718,385 137,563,877 Stock options 2,872,491 4,571,301 RSU awards 67,547 11,589 Weighted-average common shares outstanding—Diluted (1) 142,658,423 142,146,767 Net income per share—Basic $ 0.17 $ 0.57 Net income per share—Diluted $ 0.17 $ 0.55 (1) Excludes weighted-average Sponsor Vesting Shares subject to return of 4,500,000 shares for the year ended December 31, 2023 and 2022. |
Summary of Antidilutive Securities Excluded from Computation of Earnings per Share | The following potentially dilutive securities for common stock were outstanding and excluded from diluted earnings per share as they are subject to performance or market conditions that were not probable of being achieved as follows: Year Ended December 31, 2023 2022 Options to purchase common stock 1,481,531 1,481,531 Performance-based stock awards 2,018,934 2,218,925 Earnout shares 25,000,000 25,000,000 Sponsor vesting shares 4,500,000 4,500,000 The following outstanding shares of out-of-the-money options and potentially dilutive warrants were excluded from the computation of diluted net income per sha re attributable to common stockholders for the periods presented because including them would have been antidilutive: Year Ended December 31, 2023 2022 Options to purchase common stock 41,357 — Warrants to purchase common stock 35,476,667 35,476,667 |
Organization and Business - Nar
Organization and Business - Narrative (Details) $ in Billions | Dec. 31, 2023 USD ($) |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Market size | $ 65 |
Overall total market size | $ 1,000 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Narrative (Detail) | 1 Months Ended | 12 Months Ended | ||
Nov. 30, 2023 | Dec. 31, 2023 USD ($) segment plan $ / shares shares | Dec. 31, 2022 USD ($) shares | Sep. 27, 2019 USD ($) | |
Significant Accounting Policies [Line Items] | ||||
Escrow deposit fair value | $ 1,300,000 | |||
Escrow deposit | $ 0 | $ 300,000 | ||
Impairment of long lived assets | $ 0 | $ 0 | ||
Exercise price (in dollars per share) | $ / shares | $ 11.50 | |||
Outstanding warrants (in shares) | shares | 35,476,627 | 35,476,627 | ||
Percent of occurrence of a tender offer or exchange of our stockholders | 50% | |||
Number of equity incentive plans (in plans) | plan | 3 | |||
Number of operating segments (in segments) | segment | 1 | |||
Total assets | $ 461,834,000 | $ 493,700,000 | ||
Workforce reduction | ||||
Significant Accounting Policies [Line Items] | ||||
Workforce reduction percentage | 30% | |||
Public warrants | ||||
Significant Accounting Policies [Line Items] | ||||
Number of warrants assumed (in shares) | shares | 24,149,960 | |||
Outstanding warrants (in shares) | shares | 24,149,960 | |||
Private placement warrants | ||||
Significant Accounting Policies [Line Items] | ||||
Number of warrants assumed (in shares) | shares | 11,326,667 | |||
Outstanding warrants (in shares) | shares | 11,326,667 | |||
Maximum | ||||
Significant Accounting Policies [Line Items] | ||||
Payments due (in days) | 90 days | |||
Intangible assets, estimated useful lives | 15 years | |||
Minimum | ||||
Significant Accounting Policies [Line Items] | ||||
Payments due (in days) | 30 days | |||
Intangible assets, estimated useful lives | 7 years | |||
Outside United States | ||||
Significant Accounting Policies [Line Items] | ||||
Total assets | $ 206,100,000 | 157,200,000 | ||
Standby Letters of Credit | ||||
Significant Accounting Policies [Line Items] | ||||
Letter of credit | $ 0 | $ 200,000 | ||
Top two customers | Revenue benchmark | Product concentration risk | ||||
Significant Accounting Policies [Line Items] | ||||
Concentration risk, percentage | 67% | |||
Top two customers | Revenue benchmark | Customer concentration risk | ||||
Significant Accounting Policies [Line Items] | ||||
Concentration risk, percentage | 77% |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Accounting Policies [Abstract] | |||
Cash and cash equivalents | $ 75,502 | $ 107,858 | |
Restricted cash | 0 | 490 | |
Total cash, cash equivalents, and restricted cash | $ 75,502 | $ 108,348 | $ 47,127 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Schedule of Allowance for Credit Loss (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Accounting Policies [Abstract] | ||
Accounts receivable, gross | $ 15,204 | $ 0 |
Allowance for credit loss | 0 | 0 |
Unbilled receivable | 924 | 0 |
Accounts receivable, net | $ 16,128 | $ 0 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail) | Dec. 31, 2023 |
Computer equipment and software | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 3 years |
Lab equipment | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 5 years |
Furniture, fixtures, and machinery | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 5 years |
Land improvements and infrastructure | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 20 years |
Manufacturing equipment and pilot plant | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 25 years |
Buildings | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 40 years |
Revenue (Detail)
Revenue (Detail) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Revenue from Contract with Customer [Abstract] | ||
Deferred income | $ 0 | $ 0 |
Fair Value Measurement - Summar
Fair Value Measurement - Summary of Assets And Liabilities Measured At Fair Value (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Assets: | |||
Marketable securities | $ 82,761 | $ 215,464 | |
Liabilities: | |||
Earnout liability | 1,783 | $ 42,533 | $ 127,757 |
Derivative Liability, Statement of Financial Position [Extensible Enumeration] | Derivative liability | ||
Recurring | |||
Assets: | |||
Cash, cash equivalents and restricted cash | 75,502 | $ 108,348 | |
Marketable securities | 82,761 | 215,464 | |
Total fair value | 158,263 | 323,812 | |
Liabilities: | |||
Earnout liability | 1,783 | 42,533 | |
Derivative liability | 300 | 344 | |
Total fair value | 3,424 | 73,748 | |
Recurring | Common stock warrants (Public) | |||
Liabilities: | |||
Warrants or rights outstanding | 913 | 21,015 | |
Recurring | Common stock warrants (Private Placement) | |||
Liabilities: | |||
Warrants or rights outstanding | 428 | 9,856 | |
Level 1 | Recurring | |||
Assets: | |||
Cash, cash equivalents and restricted cash | 75,502 | 108,348 | |
Marketable securities | 0 | 0 | |
Total fair value | 75,502 | 108,348 | |
Liabilities: | |||
Earnout liability | 0 | 0 | |
Derivative liability | 0 | 0 | |
Total fair value | 913 | 21,015 | |
Level 1 | Recurring | Common stock warrants (Public) | |||
Liabilities: | |||
Warrants or rights outstanding | 913 | 21,015 | |
Level 1 | Recurring | Common stock warrants (Private Placement) | |||
Liabilities: | |||
Warrants or rights outstanding | 0 | 0 | |
Level 2 | Recurring | |||
Assets: | |||
Cash, cash equivalents and restricted cash | 0 | 0 | |
Marketable securities | 82,761 | 215,464 | |
Total fair value | 82,761 | 215,464 | |
Liabilities: | |||
Earnout liability | 0 | 0 | |
Derivative liability | 300 | 344 | |
Total fair value | 728 | 10,200 | |
Level 2 | Recurring | Common stock warrants (Public) | |||
Liabilities: | |||
Warrants or rights outstanding | 0 | 0 | |
Level 2 | Recurring | Common stock warrants (Private Placement) | |||
Liabilities: | |||
Warrants or rights outstanding | 428 | 9,856 | |
Level 3 | Recurring | |||
Assets: | |||
Cash, cash equivalents and restricted cash | 0 | 0 | |
Marketable securities | 0 | 0 | |
Total fair value | 0 | 0 | |
Liabilities: | |||
Earnout liability | 1,783 | 42,533 | |
Derivative liability | 0 | 0 | |
Total fair value | 1,783 | 42,533 | |
Level 3 | Recurring | Common stock warrants (Public) | |||
Liabilities: | |||
Warrants or rights outstanding | 0 | 0 | |
Level 3 | Recurring | Common stock warrants (Private Placement) | |||
Liabilities: | |||
Warrants or rights outstanding | $ 0 | $ 0 |
Fair Value Measurement - Narrat
Fair Value Measurement - Narrative (Detail) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Class of Warrant or Right [Line Items] | ||
Gain in fair value of earnout liability | $ 40,983,000 | $ 85,437,000 |
Sales of marketable securities | 3,605,216,000 | 3,815,859,000 |
Realized gain (loss) on marketable securities | 1,000,000 | (1,000,000) |
Aggregate fair value of marketable securities in unrealized loss position | 73,200,000 | 193,500,000 |
Allowance for credit loss | 0 | 0 |
Earnout liability | ||
Class of Warrant or Right [Line Items] | ||
Gain in fair value of earnout liability | 41,000,000 | 85,400,000 |
Foreign currency contract | ||
Class of Warrant or Right [Line Items] | ||
Net gain (loss) on foreign currency derivative contracts | 100,000 | (400,000) |
Derivative, notional amount | $ 14,700,000 | $ 21,200,000 |
Fair Value Measurement - Summ_2
Fair Value Measurement - Summary of Activities of Earnout Liability (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Business Combination, Contingent Consideration, Liability [Roll Forward] | ||
Beginning balance | $ 42,533 | $ 127,757 |
Change in fair value of earnout liability | (40,983) | (85,437) |
Other | 233 | 213 |
Ending balance | $ 1,783 | $ 42,533 |
Fair Value Measurement - Summ_3
Fair Value Measurement - Summary of Marketable Securities (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | $ 86,146 | $ 225,210 |
Unrealized Gains | 52 | 46 |
Unrealized Losses | (3,437) | (9,792) |
Fair Value | 82,761 | 215,464 |
Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 21,869 | 115,134 |
Unrealized Gains | 26 | 0 |
Unrealized Losses | (847) | (4,923) |
Fair Value | 21,048 | 110,211 |
Asset-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 52,199 | 70,825 |
Unrealized Gains | 26 | 8 |
Unrealized Losses | (2,289) | (3,885) |
Fair Value | 49,936 | 66,948 |
U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 11,706 | 19,308 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | (270) | (917) |
Fair Value | 11,436 | 18,391 |
Foreign government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 372 | 375 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | (31) | (37) |
Fair Value | $ 341 | 338 |
Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 17,568 | |
Unrealized Gains | 38 | |
Unrealized Losses | 0 | |
Fair Value | 17,606 | |
Municipal/provincial bonds and other | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 2,000 | |
Unrealized Gains | 0 | |
Unrealized Losses | (30) | |
Fair Value | $ 1,970 |
Fair Value Measurement - Market
Fair Value Measurement - Marketable Security Contractual Maturities (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Total | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mature within one year | $ 30,264 | $ 104,000 |
Mature after one year through two years | 2,098 | 48,065 |
Mature over two years | 50,399 | 63,399 |
Fair Value | 82,761 | 215,464 |
Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mature within one year | 17,606 | |
Mature after one year through two years | 0 | |
Mature over two years | 0 | |
Fair Value | 17,606 | |
Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mature within one year | 20,756 | 74,797 |
Mature after one year through two years | 292 | 35,414 |
Mature over two years | 0 | 0 |
Fair Value | 21,048 | 110,211 |
Asset-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mature within one year | 238 | 1,907 |
Mature after one year through two years | 1,806 | 4,833 |
Mature over two years | 47,892 | 60,207 |
Fair Value | 49,936 | 66,947 |
U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mature within one year | 8,929 | 7,719 |
Mature after one year through two years | 0 | 7,480 |
Mature over two years | 2,507 | 3,192 |
Fair Value | 11,436 | 18,391 |
Foreign government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mature within one year | 341 | 0 |
Mature after one year through two years | 0 | 338 |
Mature over two years | 0 | 0 |
Fair Value | $ 341 | 338 |
Municipal/provincial bonds and other | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mature within one year | 1,971 | |
Mature after one year through two years | 0 | |
Mature over two years | 0 | |
Fair Value | $ 1,971 |
Property, Plant and Equipment -
Property, Plant and Equipment - Schedule of Property Plant and Equipment (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 197,231 | $ 20,029 |
Less accumulated depreciation and amortization | (8,136) | (4,693) |
Construction in process | 54,023 | 138,847 |
Total property, plant, and equipment, net | 243,118 | 154,183 |
Land | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 11,356 | 11,358 |
Land improvements and infrastructure | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 62,930 | 0 |
Estimated useful lives | 20 years | |
Manufacturing equipment and pilot plant | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 116,754 | 4,599 |
Estimated useful lives | 25 years | |
Computer equipment and software | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 1,629 | 598 |
Estimated useful lives | 3 years | |
Lab equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 3,468 | 2,526 |
Estimated useful lives | 5 years | |
Furniture, fixtures, and machinery | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 1,094 | $ 948 |
Estimated useful lives | 5 years |
Property, Plant and Equipment_2
Property, Plant and Equipment - Narrative (Detail) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 3.3 | $ 0.7 |
Capitalized interest cost | 1.5 | 1.1 |
Capitalized stock-based compensation | $ 2.3 | $ 1.9 |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Patents | $ 413 | $ 404 |
Less accumulated amortization | (292) | (244) |
Total intangible assets | $ 121 | $ 160 |
Intangible Assets - Narrative (
Intangible Assets - Narrative (Detail) | 12 Months Ended |
Dec. 31, 2023 | |
Patents | |
Finite-Lived Intangible Assets [Line Items] | |
Intangible assets weighted average useful life | 3 years 4 months 28 days |
Consortium Agreement - Narrativ
Consortium Agreement - Narrative (Detail) | 1 Months Ended | 12 Months Ended | ||
Aug. 31, 2018 USD ($) investor | Dec. 31, 2016 USD ($) investor | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Company received amount from agreement | $ 500,000 | |||
Invested amount for research and development | $ 1,500,000 | |||
Other income | $ 0 | $ 0 | ||
Consortium Agreement | Legacy Origin Series C Investor | Related party | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Company received amount from agreement | $ 0 | |||
Consortium Agreement | Legacy Origin Series B Preferred Stock | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Number of investors | investor | 2 | 2 |
Inventory (Detail)
Inventory (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Inventory Disclosure [Abstract] | ||
Finished goods | $ 24 | $ 0 |
Raw materials | 888 | 0 |
Total | $ 912 | $ 0 |
Notes Payable - Narrative (Deta
Notes Payable - Narrative (Detail) $ in Thousands | 1 Months Ended | 12 Months Ended | |||
Aug. 01, 2022 USD ($) | May 31, 2019 USD ($) installment | Nov. 30, 2016 USD ($) | Dec. 31, 2023 USD ($) agreement | Dec. 31, 2022 USD ($) | |
Debt Disclosure [Line Items] | |||||
Number of offtake supply agreements (in agreements) | agreement | 8 | ||||
Number of offtake supply agreements with same customer (in agreements) | agreement | 2 | ||||
Debt instrument, increase, accrued interest | $ 600 | $ 300 | |||
Notes payable, short-term | 1,730 | 0 | |||
Note principal outstanding | 3,459 | 5,847 | |||
Promissory note | |||||
Debt Disclosure [Line Items] | |||||
Prepayment from stockholder | $ 5,000 | ||||
Debt instrument, increase, accrued interest | $ 200 | ||||
Number of installments (in installments) | installment | 3 | ||||
Long-term debt, maturity, year two | $ 2,700 | ||||
Long-term debt, maturity, year three | 1,900 | ||||
Long-term debt, maturity, year four | $ 1,800 | ||||
Accrued interest rate | 3.50% | ||||
Other long-term debt | 5,200 | ||||
Notes payable, long-term | 3,500 | ||||
Notes payable, short-term | 1,700 | ||||
Accrued interest | $ 800 | 600 | |||
Note principal outstanding | $ 5,200 | ||||
Initial term of offtake supply agreement | 10 years | ||||
Promissory note | Legacy stockholder note | |||||
Debt Disclosure [Line Items] | |||||
Principal amount | $ 5,200 |
Other Liabilities, Long-term -
Other Liabilities, Long-term - Narrative (Detail) $ in Millions | 1 Months Ended | 12 Months Ended | |||||
Feb. 05, 2024 USD ($) | Sep. 30, 2019 USD ($) installment | Nov. 30, 2016 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2019 USD ($) | Feb. 29, 2024 USD ($) | |
Other Liabilities [Line Items] | |||||||
Number of prepayment installments (in installments) | installment | 2 | ||||||
Debt instrument accrued interest | $ 0.6 | $ 0.3 | |||||
Principal outstanding amount | $ 5.1 | 5.1 | |||||
Subsequent event | |||||||
Other Liabilities [Line Items] | |||||||
Debt instrument, periodic payment | $ 2.5 | ||||||
Payments of debt issuance costs | $ 2.5 | ||||||
Promissory Note One | |||||||
Other Liabilities [Line Items] | |||||||
Other long-term debt | $ 5 | ||||||
Debt instrument accrued interest | $ 0.1 | ||||||
Aggregate principal amount | $ 5.1 | ||||||
Repayment period under prepayment agreement | 5 years | ||||||
Amount of repayment under prepayment agreement | $ 7.5 | ||||||
Repayment percentage of prepayment agreement amount | 150% | ||||||
Loan facility interest rate | 5.61% | ||||||
Loan facility term | 5 years | ||||||
Promissory Note One | Subsequent event | |||||||
Other Liabilities [Line Items] | |||||||
Repayments of installments, one | $ 2.2 | ||||||
Repayments of installments, two | 1.6 | ||||||
Repayments of installments, three | $ 2.1 | ||||||
SOFR | Promissory Note One | |||||||
Other Liabilities [Line Items] | |||||||
Variable interest rate | 0.25% | ||||||
Prepayment agreement | |||||||
Other Liabilities [Line Items] | |||||||
Other long-term debt | $ 5 | $ 2.5 | $ 2.5 | ||||
Percentage of prepayment applied against future purchases | 100% | ||||||
Period of customer capacity reservation | 10 years | ||||||
Prepayment agreement | Installment 1 | |||||||
Other Liabilities [Line Items] | |||||||
Debt instrument, periodic payment | $ 2.5 | ||||||
Prepayment agreement | Installment 2 | |||||||
Other Liabilities [Line Items] | |||||||
Debt instrument, periodic payment | $ 2.5 | ||||||
Period of payment of prepayment agreement | 30 days |
Earnout Liability - Narrative (
Earnout Liability - Narrative (Detail) $ / shares in Units, $ in Thousands, shares in Millions | 12 Months Ended | ||
Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Business Acquisition, Contingent Consideration [Line Items] | |||
Post triggering event period | 10 days | ||
Earnout shares of common stock outstanding (in shares) | shares | 25 | ||
Sponsor vesting shares (in shares) | shares | 4.5 | ||
Earn-out liability | $ 1,783 | $ 42,533 | $ 127,757 |
Gain in fair value of earnout liability | 40,983 | 85,437 | |
Earnout liability | |||
Business Acquisition, Contingent Consideration [Line Items] | |||
Earn-out liability | 1,800 | 42,500 | |
Gain in fair value of earnout liability | $ 41,000 | $ 85,400 | |
Earnout liability | Dividend yield | |||
Business Acquisition, Contingent Consideration [Line Items] | |||
Measurement input | 0 | 0 | |
Earnout liability | Volatility | |||
Business Acquisition, Contingent Consideration [Line Items] | |||
Measurement input | 1.08 | 0.70 | |
Earnout liability | Interest rate | |||
Business Acquisition, Contingent Consideration [Line Items] | |||
Measurement input | 0.0404 | 0.0408 | |
Earnout liability | Share trigger price 1 | |||
Business Acquisition, Contingent Consideration [Line Items] | |||
Post triggering event period | 10 days | ||
Share price (in dollars per share) | $ / shares | $ 15 | ||
Period from businees combination closing date stock price trigger | 3 years | ||
Earnout liability | Share trigger price 2 | |||
Business Acquisition, Contingent Consideration [Line Items] | |||
Post triggering event period | 10 years | ||
Share price (in dollars per share) | $ / shares | $ 20 | ||
Period from businees combination closing date stock price trigger | 4 years | ||
Earnout liability | Share trigger price 3 | |||
Business Acquisition, Contingent Consideration [Line Items] | |||
Post triggering event period | 10 years | ||
Share price (in dollars per share) | $ / shares | $ 25 | ||
Period from businees combination closing date stock price trigger | 5 years |
Canadian Government Research _2
Canadian Government Research and Development Program Liability - Narrative (Detail) $ in Millions, $ in Millions | 1 Months Ended | |||
Apr. 30, 2019 CAD ($) | Dec. 31, 2024 | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||
Lesser eligible costs percentage | 18.48% | |||
Lesser eligible costs | $ 23 | |||
Funding repayment period | 15 years | |||
Maximum repayment ratio | 1.25 | |||
Minimum costs of commercial plants | $ 500 | |||
Commercial plants constructed and operational period | 30 months | |||
Funding liability | $ 7.3 | $ 7.2 | ||
Forecast | ||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||
Funding reduction percentage | 50% |
Common Stock Warrants - Narrati
Common Stock Warrants - Narrative (Detail) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Class of Warrant or Right [Line Items] | ||
Number of warrants or rights outstanding (in shares) | 35,476,627 | 35,476,627 |
Common stock warrants liability | $ 1.3 | $ 30.9 |
Change in fair value of gain, assumed warrants | $ 29.5 | $ 22 |
Share trigger price 1 | ||
Class of Warrant or Right [Line Items] | ||
Class of warrants redemption price per unit (in dollars per share) | $ 0.01 | |
Class of warrants redemption notice period | 30 days | |
Warrant instrument redemption threshold consecutive trading days | 20 days | |
Trading period | 30 days | |
Public warrants | ||
Class of Warrant or Right [Line Items] | ||
Warrants issued during the period (in shares) | 24,149,960 | |
Number of common stock shares converted (in shares) | 1 | |
Share price (in dollars per share) | $ 11.50 | |
Private placement warrants | ||
Class of Warrant or Right [Line Items] | ||
Warrants issued during the period (in shares) | 11,326,667 | |
Number of common stock shares converted (in shares) | 1 | |
Share price (in dollars per share) | $ 11.50 | |
Private warrant | ||
Class of Warrant or Right [Line Items] | ||
Share price (in dollars per share) | $ 12 | |
Warrant instrument redemption threshold consecutive trading days | 20 days | |
Trading period | 30 days | |
Minimum lock In period required for warrant exercise from the date of business combination | 365 days | |
Number of days for a particular event to get over for determining trading period | 150 days | |
Common Class A | Minimum | ||
Class of Warrant or Right [Line Items] | ||
Share redemption trigger price per share (in dollars per share) | $ 10 | |
Common Class A | Maximum | ||
Class of Warrant or Right [Line Items] | ||
Share redemption trigger price per share (in dollars per share) | 18 | |
Common Class A | Share trigger price 1 | ||
Class of Warrant or Right [Line Items] | ||
Share redemption trigger price per share (in dollars per share) | $ 18 |
Stockholders' Equity - Narrativ
Stockholders' Equity - Narrative (Detail) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
Jan. 01, 2023 | Nov. 30, 2023 | Dec. 31, 2023 | Mar. 31, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2020 | Dec. 31, 2021 | Jun. 30, 2021 | |
Class of Stock [Line Items] | |||||||||
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | ||||||
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 | 10,000,000 | ||||||
Common stock, voting rights | one | ||||||||
Common stock, shares outstanding (in shares) | 145,706,531 | 145,706,531 | 143,034,225 | ||||||
Sponsor vesting shares outstanding (in shares) | 4,500,000 | 4,500,000 | 4,500,000 | ||||||
Common stock, shares reserved (in shares) | 30,004,203 | 30,004,203 | |||||||
Total intrinsic value of options exercised | $ 2,500 | $ 8,500 | |||||||
Nonvested award, cost not yet recognized | $ 1,700 | 1,700 | |||||||
Accelerated cost | (300) | ||||||||
Incremental cost | 400 | ||||||||
Stock-based compensation | 9,400 | 7,235 | |||||||
Workforce reduction | |||||||||
Class of Stock [Line Items] | |||||||||
Workforce reduction percentage | 30% | ||||||||
Severance benefits costs | $ 200 | ||||||||
Share-based payment reversal expenses | (700) | ||||||||
Employee separation costs | |||||||||
Class of Stock [Line Items] | |||||||||
Severance benefits costs | 500 | ||||||||
General and administrative expense | |||||||||
Class of Stock [Line Items] | |||||||||
Stock-based compensation | 6,500 | 4,700 | |||||||
Research and development expense | |||||||||
Class of Stock [Line Items] | |||||||||
Stock-based compensation | $ 2,900 | $ 2,500 | |||||||
Stock Incentive Plan | More than one year from vesting commencement date | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 2.778% | ||||||||
The Stock Plans | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, exercisable period | 4 years | ||||||||
The Stock Plans | Share-based payment arrangement, nonemployee | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, exercisable period | 10 years | ||||||||
The Stock Plans | One year from the vesting commencement date | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 25% | ||||||||
Vesting period | 1 year | ||||||||
Employee stock | Employee Stock Purchase Plan (ESPP) | |||||||||
Class of Stock [Line Items] | |||||||||
Purchase price of common stock, percent | 85% | ||||||||
Number of shares authorized (in shares) | 5,639,944 | 5,639,944 | 1,846,710 | ||||||
Evergreen shares reserve feature period | 10 years | ||||||||
Percentage of fully diluted shares of common stock | 1% | ||||||||
Increase in number of shares of authorized common stock (in shares) | 3,693,420 | ||||||||
Employee stock | The Stock Plans | |||||||||
Class of Stock [Line Items] | |||||||||
Common stock, shares reserved (in shares) | 28,761,816 | 28,761,816 | |||||||
Stock options available for grant (in shares) | 10,244,412 | 10,244,412 | |||||||
Employee stock | 2021 Equity Incentive Plan | |||||||||
Class of Stock [Line Items] | |||||||||
Number of shares authorized (in shares) | 18,467,109 | ||||||||
Evergreen shares reserve feature period | 10 years | ||||||||
Percentage of fully diluted shares of common stock | 5% | ||||||||
Number of additional shares authorized (in shares) | 1,242,387 | ||||||||
Maximum percentage of share reserve, outstanding diluted stock | 15% | ||||||||
Restricted stock units (RSUs) | |||||||||
Class of Stock [Line Items] | |||||||||
Vesting period | 2 years 2 months 12 days | ||||||||
Fair value of shares vested | $ 2,700 | $ 3,600 | |||||||
Vested (in shares) | 1,919,853 | ||||||||
Shares issued (in shares) | 165,956 | ||||||||
Share-based payment arrangement expense | $ 11,400 | ||||||||
Restricted stock units (RSUs) | The Stock Plans | |||||||||
Class of Stock [Line Items] | |||||||||
Service period | 3 years | ||||||||
Restricted stock units (RSUs) | The Stock Plans | Tranche one | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 33.30% | ||||||||
Restricted stock units (RSUs) | The Stock Plans | Tranche two | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 33.30% | ||||||||
Restricted stock units (RSUs) | The Stock Plans | Tranche three | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 33.30% | ||||||||
Restricted stock units (RSUs) | 2021 Equity Incentive Plan | |||||||||
Class of Stock [Line Items] | |||||||||
Stock compensation not yet recognized, vesting period | 3 years | ||||||||
Cost not yet recognized, excluding options | $ 19,300 | $ 19,300 | |||||||
Performance shares | |||||||||
Class of Stock [Line Items] | |||||||||
Vested (in shares) | 0 | ||||||||
Unvested outstanding (in shares) | 1,202,434 | 1,202,434 | |||||||
Performance shares | The Stock Plans | Minimum | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 0% | ||||||||
Performance shares | The Stock Plans | Maximum | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 300% | ||||||||
Performance shares | 2021 Equity Incentive Plan | |||||||||
Class of Stock [Line Items] | |||||||||
Vested (in shares) | 0 | ||||||||
Share-based payment arrangement expense | $ 2,800 | ||||||||
Options to purchase common stock | |||||||||
Class of Stock [Line Items] | |||||||||
Granted (in shares) | 0 | 0 | |||||||
Stock option, aggregate intrinsic value | $ 2,263 | $ 2,263 | |||||||
Stock compensation not yet recognized, vesting period | 9 months 18 days | ||||||||
Performance and market based awards | |||||||||
Class of Stock [Line Items] | |||||||||
Granted (in shares) | 2,920,732 | ||||||||
Stock options, vested (in shares) | 529,119 | ||||||||
Performance and market based awards | First vesting | |||||||||
Class of Stock [Line Items] | |||||||||
Stock option plan, vesting percentage | 2.0833% | ||||||||
Stock options, outstanding (in shares) | 529,119 | ||||||||
Performance and market based awards | Second vesting | |||||||||
Class of Stock [Line Items] | |||||||||
Stock options, outstanding (in shares) | 2,391,613 | ||||||||
Performance-based stock | |||||||||
Class of Stock [Line Items] | |||||||||
Shares issued (in shares) | 455,368 | ||||||||
Common Stock | |||||||||
Class of Stock [Line Items] | |||||||||
Common stock, shares authorized (in shares) | 1,010,000,000 | 1,010,000,000 | 1,010,000,000 | ||||||
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||
Warrants issued (in shares) | 1,000,000,000 | 1,000,000,000 | |||||||
Common stock, shares outstanding (in shares) | 145,706,531 | 145,706,531 | 143,034,225 | ||||||
Common Stock | Restricted stock units (RSUs) | |||||||||
Class of Stock [Line Items] | |||||||||
Vested (in shares) | 40,734 |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of Stock Option Activity (Detail) - Options to purchase common stock - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Outstanding Options | ||
Beginning balance (in shares) | 6,471,062 | |
Granted (in shares) | 0 | 0 |
Exercised (in shares) | (959,143) | |
Forfeited / canceled (in shares) | (33,909) | |
Ending balance (in shares) | 5,478,010 | 6,471,062 |
Weighted Average Exercise Price | ||
Beginning balance (in dollars per share) | $ 0.17 | |
Granted (in dollars per share) | 0 | |
Exercised (in dollars per share) | 0.15 | |
Forfeited / canceled (in dollars per share) | 0.14 | |
Ending balance (in dollars per share) | $ 0.17 | $ 0.17 |
Weighted Average Remaining Contractual Life (in years) | ||
Weighted Average Remaining Contractual Life (in years) | 6 years 18 days | 7 years 3 months 14 days |
Vested and Expected to Vest | ||
Vested and expected to vest (in shares) | 5,478,010 | |
Vested and expected to vest, exercisable (in shares) | 3,501,925 | |
Weighted average exercise price, vested and expected to vest (in dollars per share) | $ 0.17 | |
Weighted average exercise price, vested and exercisable (in dollars per share) | $ 0.19 | |
Weighted average remaining contractual life, vested and expected to vest (in years) | 6 years 18 days | |
Weighted average remaining contractual life, vested and exercisable | 5 years 7 months 13 days | |
Aggregate intrinsic value, vested and expected to vest | $ 3,638 | |
Aggregate intrinsic value, vested and exercisable | $ 2,263 |
Stockholders' Equity - Summar_2
Stockholders' Equity - Summary of RSU and Performance Award Activity (Detail) | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
RSUs and performance shares | |
Outstanding | |
Beginning balance (in shares) | 6,371,950 |
Ending balance (in shares) | 13,046,104 |
Expected to vest (in shares) | 10,927,261 |
Weighted-average grant date fair value | |
Beginning balance (in dollars per share) | $ / shares | $ 6.24 |
Ending balance (in dollars per share) | $ / shares | $ 2.54 |
RSU awards | |
Outstanding | |
Granted (in shares) | 9,374,125 |
Vested (in shares) | (1,919,853) |
Forfeited (in shares) | (680,036) |
Weighted-average grant date fair value | |
Granted (in dollars per share) | $ / shares | $ 1.19 |
Vested (in dollars per share) | $ / shares | 5.49 |
Foreited (in dollars per share) | $ / shares | $ 4.89 |
Performance-based stock awards | |
Outstanding | |
Granted (in shares) | 455,368 |
Vested (in shares) | 0 |
Forfeited (in shares) | (555,450) |
Ending balance (in shares) | 1,202,434 |
Weighted-average grant date fair value | |
Granted (in dollars per share) | $ / shares | $ 0.93 |
Vested (in dollars per share) | $ / shares | 0 |
Foreited (in dollars per share) | $ / shares | $ 6.81 |
Income Taxes - Income before In
Income Taxes - Income before Income Taxes (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
United States | $ 22,481 | $ 81,269 |
Foreign | 230 | (2,700) |
Income before income tax benefits | $ 22,711 | $ 78,569 |
Income Taxes - Federal and Stat
Income Taxes - Federal and State Income Tax Provision (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Current | ||
Federal | $ 0 | $ 0 |
State | 20 | 3 |
Foreign | 139 | 0 |
Total current tax expenses | 159 | 3 |
Deferred | ||
Federal | 0 | 0 |
State | 0 | 0 |
Foreign | (1,246) | 0 |
Total deferred tax benefits | (1,246) | 0 |
Total tax expenses | $ (1,087) | $ 3 |
Income Taxes - Deferred Tax Ass
Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets | ||
Net operating loss carryforwards | $ 34,076 | $ 27,210 |
Available for sale marketable securities | 825 | 2,064 |
Lease liabilities | 1,050 | 532 |
Other | 51 | 36 |
Fixed assets and intangibles | 445 | 25 |
Capitalized research and development costs | 4,456 | 1,929 |
Stock Compensation | 2,806 | 1,544 |
Total deferred tax assets | 43,709 | 33,340 |
Deferred tax liabilities | ||
ROU asset | (1,012) | (515) |
Other | (16) | 0 |
Fixed assets and intangibles | 0 | (479) |
Total deferred tax liabilities | (1,028) | (994) |
Valuation allowance | (41,420) | (32,346) |
Net deferred taxes | $ 1,261 | $ 0 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Detail) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating Loss Carryforwards [Line Items] | ||
Increase in valuation allowance | $ 9,100,000 | $ 6,700,000 |
Federal operating loss carryforward | 139,700,000 | |
Operating loss carryforward, state | 42,800,000 | |
Operating loss carryforward, foreign | 7,200,000 | |
Unrecognized tax benefits | 0 | $ 0 |
Domestic | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforward subject to expiration | 42,000,000 | |
Operating loss carryforward not subject to expiration | 97,700,000 | |
Foreign | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforward, research | $ 30,000 |
Income Taxes - Effective Tax Ra
Income Taxes - Effective Tax Rate (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Increase (Decrease) in Tax Rate: | ||
Statutory rate | 21% | 21% |
State tax | (12.20%) | 1.10% |
Foreign tax | 0.60% | 0% |
Warrants and other equity items | (65.30%) | (28.70%) |
Valuation allowance | 46.80% | 6.40% |
Other | 0.50% | 0.70% |
Foreign rate differential | 0.60% | (0.20%) |
Stock-based compensation | 3.20% | (0.30%) |
Effective income tax rate | (4.80%) | 0% |
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] | ||
Statutory rate | $ 4,769 | $ 16,500 |
State tax | (2,761) | 875 |
Foreign tax | 139 | 0 |
Warrants and other equity items | (14,808) | (22,559) |
Valuation allowance | 10,629 | 5,040 |
Other | 98 | 502 |
Foreign rate differential | 128 | (148) |
Stock-based compensation | 719 | (207) |
Total tax expenses | $ (1,087) | $ 3 |
Leases - Narrative (Detail)
Leases - Narrative (Detail) | Dec. 31, 2023 |
Minimum | |
Lessee, Lease, Description [Line Items] | |
Remaining operating lease term | 1 year |
Maximum | |
Lessee, Lease, Description [Line Items] | |
Remaining operating lease term | 10 years |
Leases - Components of Lease Co
Leases - Components of Lease Cost (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Leases [Abstract] | ||
Operating lease cost | $ 807 | $ 671 |
Variable lease cost | 109 | 107 |
Total lease cost | $ 916 | $ 778 |
Leases - Other Information (Det
Leases - Other Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Right of Use Assets: | ||
Operating lease ROU asset | $ 4,468 | $ 2,779 |
Weighted average remaining lease term (in years): | ||
Operating leases | 9 years 5 months 26 days | 5 years 3 months 10 days |
Weighted average discount rate: | ||
Operating leases | 7.40% | 3.40% |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Operating cash flows from operating leases | $ 726 | $ 572 |
Right-of-Use Asset Obtained In Exchange for Lease Liability: | ||
Operating lease ROU assets obtained in exchange for lease obligations | $ 2,308 | $ 1,687 |
Leases - Operating Lease Maturi
Leases - Operating Lease Maturity (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Leases [Abstract] | ||
2024 | $ 687 | |
2025 | 636 | |
2026 | 607 | |
2027 | 595 | |
2028 | 612 | |
Thereafter | 3,348 | |
Total lease payments | 6,485 | |
Less: imputed interest | (1,911) | |
Less: operating lease liabilities, current | (367) | $ (619) |
Operating lease liabilities, non-current | $ 4,207 | $ 2,249 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Detail) | 1 Months Ended | 12 Months Ended | |||||||
Jul. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Nov. 30, 2016 USD ($) | Apr. 30, 2023 USD ($) | May 31, 2018 USD ($) | Sep. 30, 2011 USD ($) | Jun. 30, 2011 USD ($) | Dec. 31, 2023 USD ($) case | Dec. 31, 2022 USD ($) | |
Other Commitments [Line Items] | |||||||||
Take-Or-Pay basis, term | 5 years | ||||||||
Take-Or-Pay basis, contract cost | $ 33,000,000 | ||||||||
Purchase obligation | 5,000,000 | ||||||||
Purchase obligation, minimum, amount | $ 7,000,000 | ||||||||
Advance payment | $ 11,500,000 | ||||||||
License payment, royalty payment | $ 0 | $ 0 | |||||||
Number of cases (in claims) | case | 2 | ||||||||
Operating and Maintenance Agreement | |||||||||
Other Commitments [Line Items] | |||||||||
Service agreement, periods | 5 years | ||||||||
Operating and maintenance agreements, automatic extension periods | 1 year | ||||||||
Property, plant, and equipment, net | $ 600,000 | 1,500,000 | |||||||
Operating and Maintenance Agreement | Minimum | |||||||||
Other Commitments [Line Items] | |||||||||
Operating and maintenance agreements, fixed payments per year | $ 400,000 | ||||||||
Nonexclusive Patents License Agreement | |||||||||
Other Commitments [Line Items] | |||||||||
Percentage of net sales | 0.40% | ||||||||
Patent License Agreement | |||||||||
Other Commitments [Line Items] | |||||||||
License agreement amount | $ 100,000 | $ 500,000 | |||||||
Royalty payment per year | $ 100,000 | ||||||||
Royalty payment, cumulative amount | 500,000 | $ 10,000,000 | |||||||
Upfront license fee royalty and a variable royalty, aggregate cap per facility | $ 10,000,000 | ||||||||
License payment, royalty payment | 0 | 0 | |||||||
Patent License Agreement | Minimum | |||||||||
Other Commitments [Line Items] | |||||||||
Royalty payment per year | $ 100,000 | ||||||||
Patent License Agreement | Maximum | |||||||||
Other Commitments [Line Items] | |||||||||
Royalty payment per year | $ 100,000 | ||||||||
Royalty payment, cumulative amount | $ 1,000,000 | $ 2,000,000 | |||||||
Nonexclusive Patents Llicense Agreement | |||||||||
Other Commitments [Line Items] | |||||||||
License agreement amount | $ 5,000,000 | ||||||||
Additional payments for license agreement | $ 7,900,000 |
Basic and Diluted Net Income _3
Basic and Diluted Net Income Per Share - Summary of Basic And Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Numerator: | ||
Net income attributable to common stockholders—Basic | $ 23,798 | $ 78,569 |
Net income attributable to common stockholders—Diluted | $ 23,798 | $ 78,569 |
Denominator: | ||
Weighted-average common shares outstanding—Basic (in shares) | 139,718,385 | 137,563,877 |
Weighted-average common shares outstanding—Diluted (in shares) | 142,658,423 | 142,146,767 |
Net income per share—Diluted (in dollars per share) | $ 0.17 | $ 0.57 |
Net income per share—Diluted (in dollars per share) | $ 0.17 | $ 0.55 |
Weighted-average sponsor vesting shares subject to return (in shares) | 4,500,000 | 4,500,000 |
Options to purchase common stock | ||
Denominator: | ||
Dilutive share based payment arrangements (in shares) | 2,872,491 | 4,571,301 |
RSU awards | ||
Denominator: | ||
Dilutive share based payment arrangements (in shares) | 67,547 | 11,589 |
Basic and Diluted Net Income _4
Basic and Diluted Net Income Per Share - Narrative (Detail) - shares shares in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Earnings Per Share [Abstract] | ||
Weighted-average sponsor vesting shares subject to return (in shares) | 4.5 | 4.5 |
Basic and Diluted Net Income _5
Basic and Diluted Net Income Per Share - Summary of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Detail) - shares | 3 Months Ended | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | |
Options to purchase common stock | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 41,357 | 0 | |
Options to purchase common stock | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 1,481,531 | 1,481,531 | |
Performance shares | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 2,018,934 | 2,218,925 | |
Earnout shares | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 25,000,000 | 25,000,000 | |
Sponsor vesting shares | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 4,500,000 | 4,500,000 | |
Warrants to purchase common stock | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 35,476,667 | 35,476,667 |